Methods of enhancing adoptive cell transfer immunotherapy

By using protein treatments with IgG cysteine ​​protease or IgG endoglucosidase activity in adoptive cell transfer immunotherapy, the survival and activity of CAR T cells stimulated by plasma immunoglobulins have been addressed, improving efficacy, particularly in the treatment of cancer and autoimmune diseases.

CN119013396APending Publication Date: 2024-11-22HANSA BIOPHARMA AB
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202280088910.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2021-11-15
Filing Date
2022-11-14
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

In existing adoptive cell transfer immunotherapy targeting immunoglobulin light chains, the survival and sustained activity of CAR T cells are limited by the stimulation and binding of immunoglobulins in plasma, leading to reduced efficacy, and antibody-mediated effector mechanisms affect cell function.

Method used

Combined administration of proteins with IgG cysteine ​​protease or IgG endoglucosidase activity, such as IdeS and EndoS, removes or inactivates immunoglobulins in plasma, reduces the impact of antibody-mediated effector mechanisms on CAR T cells, and improves cell survival and activity.

Benefits of technology

It enhanced the survival and activity of CAR T cells, improved the efficacy of adoptive cell transfer immunotherapy, especially in the treatment of cancer and autoimmune diseases, and reduced antibody-mediated complement deposition, phagocytosis and receptor activation-induced cell death.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119013396A_ABST
    Figure CN119013396A_ABST
Patent Text Reader

Abstract

The present invention relates to a method of enhancing adoptive cell transfer immunotherapy targeting immunoglobulin light chains by administering a protein having IgG cysteine protease or IgG endoglycosidase activity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to improvements in adoptive cell transfer immunotherapy targeting immunoglobulin light chains. Background Art

[0002] Adoptive cell transfer immunotherapy is a newly established class of therapeutics used to treat a variety of diseases, including cancer. For the treatment of solid or hematopoietic tumors, the patient's T cells are expanded ex vivo, ideally specific for tumor-associated antigens, and then infused back. T cell number, specificity, activity, and efficacy have been limiting factors for these treatments. A typical factor for tumor escape is the downregulation of HLA required for presentation of tumor antigens.

[0003] Chimeric antigen receptor (CAR) transfected cells are an emerging area of ​​cell-based immunotherapy that exploits the inherent cytolytic potential of a patient's own NK cells and T cells. These modified autologous cells can be used to combat B-cell malignancies or solid tumors, such as colon or breast cancer, by introducing chimeric antigen receptors (CARs) expressed on the cell surface that derive their specificity from tumor-specific scFv domains. T cells expressing chimeric antigen receptors (CARs) combine the anti-tumor activity of cytotoxic T cells with the specificity and affinity of scFv elements derived from antibodies specific for tumor-associated antigens. Sufficient numbers of autologous T cells can be harvested from the patient and then transfected with the selected CAR in vitro. Further expansion provides large numbers of HLA-independent, tumor-specific cytotoxic T cells.

[0004] Adoptive cell transfer immunotherapy targeting immunoglobulin light chains is being developed for the treatment of lymphoid malignancies (Ranganathan et al., Clin Cancer Res, 2021 and Vera et al., Blood 2006; 108). B lymphocytes express surface monoclonal immunoglobulins with either κ or λ light chains, as do many lymphoid malignancies. Therefore, adoptive cell transfer immunotherapy targeting immunoglobulin light chains expressed by lymphoid malignancies is expected to have anticancer activity. This adoptive cell transfer immunotherapy is also expected to have minimal adverse effects on patient immunity, as non-cancerous cells expressing other immunoglobulin light chain lineages will not be affected by adoptive cell transfer immunotherapy.

[0005] The efficacy of CAR T cell (CAR-T) therapy may be limited by the survival and sustained activity of CAR T cells in patients after injection. However, factors that limit CAR T cell survival and efficacy remain poorly studied and controversial. Although humoral responses against CAR T cells can theoretically trigger antibody-mediated effector mechanisms, there is little direct evidence that factors that limit CAR T cell success are caused by antibodies. Instead, tumor escape due to loss of target antigens such as CD19 (Majzner and Mackall, 2018, Cancer Discov., 8(10): 1219–26), lack of multifunctional CART cells (Rossi et al., 2018, Blood, 132(8): 804-814), or lack of tumor infiltration (Newick et al., 2017, Annu. Rev. Med. 68: 139-152) are concerns about the success of CAR T cells. Repeated infusion failure is often attributed to T cell-mediated cytotoxicity caused by mouse peptide presentation (e.g., scFv on HLA of CAR T cells) (Turtle et al., -2016, J. Clin. Invest., 126(6):2123–2138). Consistent with this, it is said that the FDA-approved CAR T cell tisagenlecleucel (Kymriah) is not affected by pre-existing and induced humoral immunity (Thudium-Muller, J. Clin. Oncology, 36(15), 2018).

[0006] The immunoglobulin G-degrading cysteine ​​protease imlifidase (IdeS) is an IgG endopeptidase that is currently being developed as a rapid desensitization treatment in renal transplantation. Imlifidase is highly specific and can cleave all subclasses of human IgG. Imlifidase can be used to reduce competition for Fc receptors when administering antibody drug products (WO 2016 / 012285).

[0007] There is a need for improved methods of treating cancer. Summary of the invention

[0008] The present invention provides a method for improving the benefits of adoptive cell transfer immunotherapy targeting immunoglobulin light chains to patients, the method comprising administering a protein with IgG cysteine ​​protease or IgG endoglycosidase activity in combination with adoptive cell transfer immunotherapy. The inventors have determined that the efficacy of adoptive cell transfer immunotherapy targeting immunoglobulin light chains may be reduced due to the stimulation of cells by immunoglobulins in plasma, resulting in cell failure and functional impairment. In addition, the limited survival and sustained activity of transfer cells (such as CAR-T cells) may limit the efficacy of adoptive cell transfer immunotherapy targeting immunoglobulin light chains. The inventors have shown in the embodiments that proteins with IgG cysteine ​​protease or IgG endoglycosidase activity can remove soluble immunoglobulins and / or inactivate soluble immunoglobulins, reduce tumor cell stimulation, and thus improve anticancer activity. In addition, the efficacy of adoptive cell transfer immunotherapy targeting immunoglobulin light chains may be reduced due to the binding of cell surface receptors to soluble immunoglobulins, thereby blocking the interaction between adoptive cell transfer immunotherapy and target tumor cells. Proteins with IgG cysteine ​​protease or IgG endoglycosidase activity may effectively digest soluble antibodies and increase the binding of receptors to their targets on tumors. The inventors also show in the embodiments that proteins with IgG cysteine ​​protease or IgG endoglycosidase activity can protect metastatic cells. In particular, the inventors have confirmed that cell surface receptor-specific antibodies (including pre-existing antibodies and antibodies produced after administration of metastatic cells) can reduce the potential of metastatic cells, and the therapeutic effect of metastatic cells will benefit from removing antibody effector functions by regulating the recipient. Soluble antibodies combined with the adoptive cell transfer immunotherapy of targeted immunoglobulin light chains may also produce similar deleterious effects on metastatic cells. Therefore, the use of proteins with IgG cysteine ​​protease or IgG endoglycosidase activity can improve the survival and activity of metastatic cells, and provide improved adoptive cell transfer immunotherapy treatment. The inventors have also confirmed that cell surface receptor-specific antibodies (such as cell surface receptor-specific antibodies for receptor constructs of CAR-T cells and other cell-based therapeutics) can interfere with the interaction between the receptor and its target protein, while proteins with IgG cysteine ​​protease or IgG endoglycosidase activity are effective for digesting antibodies and increasing the binding of the receptor to its target.

[0009] As shown in the examples, treatment with IgG cysteine ​​protease imlifidase (IdeS) can reduce or prevent CAR-T cells targeting immunoglobulin light chains in the presence of soluble immunoglobulins from producing cytokines. As further demonstrated in the examples, treatment with IgG cysteine ​​protease imlifidase (IdeS) and IgG endoglycosidase EndoS alleviates some of the restrictive effector functions of antibodies against CAR-T cells and other cell-based therapeutic agents. Therefore, the present invention provides a method for improving the benefits of adoptive cell transfer immunotherapy targeting immunoglobulin light chains to patients, the method comprising administering a protein having IgG cysteine ​​protease or IgG endoglycosidase activity in combination with adoptive cell transfer immunotherapy. In a preferred embodiment, the present invention provides a method for treating cancer, particularly B cell tumors, comprising administering a protein having IgG cysteine ​​protease or IgG endoglycosidase activity in combination with adoptive cell transfer immunotherapy targeting immunoglobulin light chains.

[0010] A limiting factor of CAR-T therapy and other adoptive cell transfer immunotherapies targeting immunoglobulin light chains may be the binding of anti-κ and anti-λ CAR constructs to immunoglobulins in plasma. This may cause stimulation of CAR-T cells outside the tumor, leading to cell exhaustion and functional impairment. Therefore, in the presence of soluble immunoglobulins in the patient, CAR-T may fail faster and fail to achieve maximum tumor cell toxicity. In addition, soluble immunoglobulins can block the interaction between CAR-T therapy and its target on tumor cells. According to the present invention, IgG cysteine ​​proteases and IgG endoglycosidases can be used to reduce the extratumoral stimulation and binding of plasma immunoglobulins to CAR-T cells. Even if plasma immunoglobulins are not completely destroyed (e.g., leaving antibody fragments), any cutting of plasma immunoglobulins will reduce their stability and half-life, thereby reducing their deleterious effects on CAR-T cells. In addition, the cutting of immunoglobulins may prevent the cross-linking between CAR and FcgR, which may otherwise cause extratumoral activation and exhaustion.

[0011] Another limiting factor of CAR-T therapy and other adoptive cell transfer immunotherapies may be that naturally occurring pre-existing antibodies against CAR constructs affect their efficacy through different antibody-mediated effector mechanisms, such as complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP), antibody-dependent cellular cytotoxicity (ADCC), exhaustion caused by tonic stimulation, or cell death induced by receptor activation. After injection, such antibodies can reduce the survival and sustained activity of CAR T cells in the patient. Infused CAR-T cells may even induce elevated levels of antibodies against the chimeric receptor, thereby preventing the interaction of CAR with its target cells during the first course of treatment and limiting their expansion and persistence. The success of the second round of treatment may be more challenging due to increased levels of anti-drug antibodies (ADA) and potentially higher affinity. Although CAR T cells are autologous, the changes introduced by the chimeric receptor and the expression of viral antigens during T cell transfection make CAR T cells vulnerable to host immune responses. Some immunogenic parts can be connecting regions between receptor components, but the most prominent is the scFv part, for example, in the early stages of CAR-T development, the scFv part was taken from tumor-specific mouse IgG. Although subsequent CAR constructs generally use humanized IgG to reduce the number of exogenous epitopes, these scFvs still contain new epitopes in the antigen binding domain. It has been shown that these exogenous epitopes can be antigens that host T cells react to, thereby limiting the survival of CAR T cells (Harding et al., 2010, MAbs, 2 (3): 256-65, Meunier et al., 2019, Cell. & Mol. Immunology). On the contrary, the data in the examples show that proteins with IgG cysteine ​​protease or IgG endoglycosidase activity can increase the survival and activity of metastatic cells and provide improved treatment by inactivation of cell surface receptor-specific antibodies. Soluble antibodies associated with adoptive cell transfer immunotherapy targeting immunoglobulin light chains can also activate similar antibody-mediated effector mechanisms against transferred cells, and proteins having IgG cysteine ​​protease or IgG endoglycosidase activity according to the present invention can be used to reduce these negative effects.

[0012] The possible mechanisms by which the activity, expansion, and survival of transferred cells (such as CAR T cells) may be affected by antibodies are different. For example, CAR-specific antibodies can promote the destruction of CAR T cells with the aid of complement deposition CDC and / or ADCP. In addition, soluble antibodies that bind to cell surface receptors can also promote the destruction of CAR-T cells by the same mechanism. These examples show that proteins with IgG cysteine ​​protease or IgG endoglycosidase activity can effectively alleviate these processes, thereby improving adoptive cell transfer immunotherapy. The binding of the antibody itself to the receptor may also lead to ADCC, exhaustion, or cell death induced by receptor activation. Proteins with IgG cysteine ​​protease or IgG endoglycosidase activity will also be useful in alleviating these processes.

[0013] In view of these developments, the present invention provides a method for improving the benefits of adoptive cell transfer immunotherapy targeting immunoglobulin light chains to patients, the method comprising administering a protein having IgG cysteine ​​protease or IgG endoglycosidase activity in combination with adoptive cell transfer immunotherapy targeting immunoglobulin light chains. Preferably, immunotherapy is cancer therapy, more preferably B cell tumor therapy. In other embodiments, immunotherapy is antibody-mediated autoimmune disease therapy. Optionally, the disease is selected from the group consisting of: juvenile arthritis (particularly juvenile idiopathic arthritis), rheumatoid arthritis, systemic lichen myxedema (sclerosing myxedema), Graves' disease, IgA-driven bullous dermatosis, IgG4-driven bullous pemphigoid, Sjogren's syndrome and lupus mastitis.

[0014] In certain embodiments, the protein is administered before adoptive cell transfer immunotherapy. The prior administration of the protein can remove immunoglobulins from the plasma and / or inactivate the immunoglobulins, and maximize the anti-cancer activity of the cells when administered. The embodiment shows that IdeS and EndoS effectively inactivate pre-existing antibodies, for example, it is effective to use IdeS and EndoS before adding a complement source or effector cells. The embodiment also shows that antibodies present in the serum of healthy individuals and HLA-sensitized patients who have not been administered adoptive cell transfer immunotherapy can bind to receptor constructs and cells such as CAR T cells and mediate harmful effects (such as ADCP, ADCC and interference with target binding (for example, such allogeneic antibodies can be caused by pregnancy or transfusion)), all of which can be reduced by IdeS treatment. In certain embodiments, the protein is administered after the administration of adoptive cell transfer immunotherapy. The embodiment shows that IdeS and EndoS can effectively inactivate induced antibodies because immune thrombocytopenia is reduced when Ides and EndoS are administered after anti-platelet-specific antibodies. The examples also show that allogeneic antibodies present in human serum can have a negative effect on adoptive cell transfer immunotherapy cells (e.g., CAR-T cells), and the proteins of the present invention can reduce or prevent such negative effects. Adoptive cell transfer immunotherapy can induce such allogeneic antibodies, so the proteins of the present invention may be useful when administered after the administration of adoptive cell transfer immunotherapy.

[0015] The present invention also provides a method for improving the benefit of adoptive cell transfer immunotherapy to patients, prolonging the survival of cells administered as part of adoptive cell transfer and / or enhancing their proliferation, adjusting or preparing patients for adoptive cell transfer immunotherapy, reducing plasma IgG levels or reducing the binding of complement and / or Fc receptors to plasma IgG molecules in patients undergoing or planning to undergo adoptive cell transfer immunotherapy, wherein the method comprises administering a protein having IgG cysteine ​​protease or IgG endoglycosidase activity. The effects shown in the embodiments of the polypeptides of the present invention will provide significant benefits in such methods. Preferably, the immunotherapy is a cancer therapy, more preferably a B cell tumor therapy.

[0016] The present invention also provides a method for increasing the efficacy of adoptive cell transfer therapy or increasing the binding between a cell surface receptor of adoptive cell transfer therapy and its target, the method comprising administering a protein having IgG cysteine ​​protease or IgG endoglycosidase activity before, after or simultaneously with adoptive cell transfer immunotherapy targeting immunoglobulin light chains. The embodiments demonstrate that the polypeptides of the present invention effectively increase such efficacy and binding. In preferred embodiments of this type, the target is a κ light chain or a λ light chain, and preferably the cell surface receptor is an anti-κ or anti-λ CAR.

[0017] In certain embodiments of any method of the present invention, a protein having IgG cysteine ​​protease or IgG endoglycosidase activity improves the benefits of adoptive cell transfer immunotherapy to patients or improves the treatment of cancer by removing and / or inactivating immunoglobulins in plasma that are bound by adoptive cell transfer immunotherapy and cause cell failure. In addition, in certain embodiments of any method of the present invention, a protein having IgG cysteine ​​protease or IgG endoglycosidase activity improves the benefits of adoptive cell transfer immunotherapy to patients or improves the treatment of cancer by removing IgG antibodies that inhibit the binding of cell surface receptors of adoptive cell transfer therapy to their targets. The antibody can bind to a cell surface receptor, particularly CAR, or can bind to a CAR adapter molecule, or can bind to the target itself, and can spatially hinder the binding between the receptor and its target.

[0018] In a preferred embodiment, the method of the invention uses an IgG cysteine ​​protease. In a particularly preferred embodiment, the IgG cysteine ​​protease is an IdeS or IdeZ polypeptide, most preferably an IdeS polypeptide, such as a polypeptide having a sequence at least 80% identical to SEQ ID NO: 2, 4, 5 or 91, such as at least 85%, 90%, 95% or 99% identical. The examples show that such polypeptides are effective in protecting cells and removing and / or inactivating circulating immunoglobulins.

[0019] In other embodiments, the IgG endoglycosidase is an EndoS polypeptide, such as a polypeptide having a sequence at least 80% identical, such as at least 85%, 90%, 95% or 99% identical to SEQ ID NO: 90. The examples show that such polypeptides are effective in protecting cells and removing and / or inactivating circulating immunoglobulins.

[0020] In a particularly preferred embodiment of the present invention, the method comprises administering an IdeS polypeptide in combination with a CAR-T therapy targeting an immunoglobulin light chain, preferably for the treatment of B cell tumors.

[0021] In a particularly preferred embodiment, the method of the invention comprises administering an IdeS polypeptide prior to adoptive cellular immunotherapy, for example, administering an IdeS polypeptide to a patient who is scheduled to receive adoptive cellular immunotherapy targeting immunoglobulin light chains. Such methods will reduce plasma immunoglobulins that would otherwise be depleted and reduce the effectiveness of the cellular therapy, or that might block the interaction between the cellular therapy and its target on tumor cells.

[0022] The present invention also provides a composition, in particular a pharmaceutical composition, for use in the method of the present invention, comprising a protein having IgG cysteine ​​protease or IgG endoglycosidase activity.

[0023] In a preferred embodiment of any aspect of the present invention, the adoptive cellular immunotherapy does not express a protein with IgG cysteine ​​protease or IgG endoglycosidase activity. In a preferred embodiment of any aspect of the present invention, the protein with IgG cysteine ​​protease or IgG endoglycosidase activity will be applied to the patient in the form of a separated protein or a composition comprising separated protein. This arrangement is advantageous because the protein with IgG cysteine ​​protease or IgG endoglycosidase activity is not directly associated with metastatic cells, and therefore is unlikely to cut the immunoglobulin light chain expressed by tumor cells. Even if the adoptive cellular immunotherapy and the protein with IgG cysteine ​​protease or IgG endoglycosidase activity are applied simultaneously, they can also be applied separately in the form of separated compositions. This method is expected to be particularly effective, for example because they can provide systemic removal or inactivation of plasma immunoglobulin to maximize the activity of the adoptive cellular immunotherapy applied.

[0024] In certain embodiments of the invention, proteins having IgG cysteine ​​protease or IgG endoglycosidase activity are used to inactivate soluble immunoglobulins directed against adoptive cellular immunotherapy, but not to inactivate anti-drug antibodies directed against adoptive cellular immunotherapy. In certain embodiments, patients treated according to the invention do not have anti-drug antibodies directed against adoptive cellular immunotherapy, or are not expected or suspected of having such antibodies.

[0025] Other embodiments of the invention are provided in the following numbered paragraphs.

[0026] 1. A method for improving the benefit of adoptive cell transfer immunotherapy targeting immunoglobulin light chains to a patient, comprising administering a protein having IgG cysteine ​​protease or IgG endoglycosidase activity in combination with the adoptive cell transfer immunotherapy.

[0027] 2. A method for treating cancer comprising administering a protein having IgG cysteine ​​protease or IgG endoglycosidase activity in combination with adoptive cell transfer immunotherapy targeting immunoglobulin light chains.

[0028] 3. A method according to any of the preceding embodiments, wherein the protein having IgG cysteine ​​protease or IgG endoglycosidase activity is administered before the adoptive cell transfer immunotherapy, or wherein the protein having IgG cysteine ​​protease or IgG endoglycosidase activity is administered after the adoptive cell transfer immunotherapy, or wherein the protein having IgG cysteine ​​protease or IgG endoglycosidase activity is administered before the administration of a second or subsequent adoptive cell transfer immunotherapy.

[0029] 4. A method for treating cancer comprising administering a protein having IgG cysteine ​​protease or IgG endoglycosidase activity to a patient who has previously received and / or is scheduled to receive adoptive cell transfer immunotherapy targeting immunoglobulin light chains.

[0030] 5. A method for treating cancer comprising administering adoptive cell transfer immunotherapy targeting immunoglobulin light chains to a patient who has previously received and / or is scheduled to receive a protein having IgG cysteine ​​protease or IgG endoglycosidase activity.

[0031] 6. A method for treating an antibody-mediated autoimmune disease, wherein the treatment comprises administering adoptive cell transfer immunotherapy targeting immunoglobulin light chains to a patient who has previously received and / or is scheduled to receive a protein having IgG cysteine ​​protease or IgG endoglycosidase activity;

[0032] Optionally, the antibody-mediated autoimmune disease is selected from the group consisting of: juvenile arthritis (particularly juvenile idiopathic arthritis), rheumatoid arthritis, generalized lichen myxedema (scleromyxedema), Graves' disease, IgA-driven bullous dermatosis, IgG4-driven bullous pemphigoid, Sjögren's syndrome and lupus mastitis.

[0033] 7. A method according to any of the preceding embodiments, wherein the adoptive cell transfer immunotherapy comprises administering T cells, natural killer cells or dendritic cells expressing a chimeric antigen receptor or a T cell receptor.

[0034] 8. A method according to embodiment 7, wherein the chimeric antigen receptor or T cell receptor comprises a binding domain, such as an scFv, which specifically binds to an immunoglobulin light chain, such as a human κ immunoglobulin light chain or a human λ immunoglobulin light chain.

[0035] 9. A method according to any of the preceding embodiments, which is a method for treating cancer, wherein the cancer is a B-cell tumor, such as a B-cell lymphoma or a B-cell leukemia.

[0036] 10. A method according to embodiment 9, wherein the cancer is selected from the group consisting of: precursor B acute lymphoblastic leukemia / lymphoblastic lymphoma (LBL), B cell acute lymphoblastic leukemia; B cell chronic lymphocytic leukemia (CLL); small lymphocytic lymphoma; B cell prolymphocytic leukemia; lymphoplasmacytic lymphoma / immunocytoma; mantle cell lymphoma; follicular lymphoma; mucosa-associated lymphoid tissue (MALT) type extranodal marginal zone B cell lymphoma; nodal marginal zone B cell lymphoma; splenic marginal zone lymphoma; hairy cell leukemia; plasmacytoma / plasma cell myeloma; diffuse large B cell lymphoma (such as primary mediastinal B cell lymphoma), Burkitt's lymphoma, Burkitt's lymphoma; primary central nervous system (CNS) lymphoma and primary intraocular lymphoma.

[0037] 11. A method according to any of the preceding embodiments, wherein the method increases the activity of cells administered in adoptive cell transfer immunotherapy.

[0038] 12. A method according to any of the preceding embodiments, wherein the method increases the survival and / or proliferation of cells administered in the adoptive cell transfer immunotherapy.

[0039] 13. A method according to any of the preceding embodiments, wherein the method reduces antibody-mediated complement fixation, complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), exhaustion and / or receptor-activated cell death of cells administered in adoptive cell transfer immunotherapy.

[0040] 14. A method according to any of the preceding embodiments, wherein:

[0041] (i) the protein having IgG cysteine ​​protease activity is an IgG cysteine ​​protease from a bacterium of the genus Streptococcus, such as Streptococcus pyogenes, optionally wherein the protein is IdeS or IdeZ; or

[0042] (ii) the protein having IgG endoglycosidase activity is an IgG endoglycosidase from a bacterium of the genus Streptococcus, such as Streptococcus pyogenes, Streptococcus equi or Streptococcus zooepidemicus, or an IgG endoglycosidase from Corynebacterium pseudotuberculosis, Enterococcus faecalis or Elizabethkingia meningoseptica, optionally wherein the protein is EndoS, CP40, EndoE or EndoF2.

[0043] 15. The method according to embodiment 14, wherein:

[0044] (i) the protein having IgG cysteine ​​protease activity is a polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 2, 4, 5 or 91 or a fragment or variant thereof having IgG cysteine ​​protease activity; or

[0045] (ii) The protein having IgG endoglycosidase activity is a polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 90 or a fragment or variant thereof having IgG endoglycosidase activity.

[0046] 16. The method according to embodiment 14, wherein:

[0047] (i) the protein having IgG cysteine ​​protease activity is a polypeptide having a sequence that is at least 80% identical, such as at least 85%, 90%, 95% or 99% identical to SEQ ID NO: 2, 4, 5 or 91, or wherein the IgG cysteine ​​protease comprises or consists of the sequence of any one of SEQ ID NO: 6-25 and 55-69, optionally wherein the sequence includes an additional methionine at the N-terminus and / or a histidine tag at the C-terminus; or

[0048] (ii) The protein having IgG endoglycosidase activity is a polypeptide having a sequence that is at least 80% identical to SEQ ID NO:90, such as at least 85%, 90%, 95% or 99% identical.

[0049] 17. A protein having IgG cysteine ​​protease or IgG endoglycosidase activity for use in regulating or preparing a patient for adoptive cell transfer immunotherapy targeting immunoglobulin light chains.

[0050] 18. A protein having IgG cysteine ​​protease or IgG endoglycosidase activity for use in improving the benefit of adoptive cell transfer immunotherapy targeting immunoglobulin light chains to patients.

[0051] 19. A protein having IgG cysteine ​​protease or IgG endoglycosidase activity for use in reducing plasma IgG levels or reducing the binding of complement or Fc receptors to plasma IgG molecules in patients undergoing or planning to undergo adoptive cell transfer immunotherapy targeting immunoglobulin light chains. BRIEF DESCRIPTION OF THE DRAWINGS

[0052] Figure 1: Treatment with IdeS or EndoS can avoid C1q and C4d deposition on antibody-targeted Daudi cells. Daudi cells were incubated with RTX (or IgG1 isotype control) and titrated amounts of IdeS (A+B) or EndoS (C+D) for approximately 2 hours, followed by the addition of human serum complement for an additional 2 hours. Cells were aliquoted and stained with anti-human C1q (A+C) or C4d (B+D), followed by SA-PE for the final detection step. Cells were analyzed in FL2 using an Accuri C6 flow cytometer. MFI values ​​are depicted.

[0053] Figure 2 : ADCC can be prevented or improved with IdeS or EndoS. CD20-positive Daudi cells were incubated with RTX (titrated from 0.2 to 50 μg / ml) and 50 μg / ml IdeS (squares), EndoS (triangles) or culture medium (diamonds). CDC was induced by adding baby rabbit serum as a complement source. After 90 minutes of incubation, the results were normalized to the percentage of cell survival without RTX (set to 100%). Cytotoxicity was assessed using the Cell Counting Kit 8 (CCK8). The normal positive control group did not receive enzyme treatment and only RTX was titrated, which represents the maximum toxicity of RTX at the specified concentration.

[0054] Figure 3 : Opsonized target cells were treated with IdeS to prevent ADCP. Calcein-stained Daudi cells were opsonized with titrated RTX (7.5 μg / ml down to 0.01 μg / ml) and incubated with 40 μg / ml of IdeS (squares), EndoS (triangles) or no enzyme (medium only, diamonds), and then FarRed-stained THP1 effector cells were added. Cells were fixed after 2 hours of incubation and analyzed by flow cytometry in FL2 and FL4. The gated FL2-positive cells were set to 100%. The population was further divided into FL2 single-positive and FL2-FL4 double-positive cells, which is the readout of Daudi cells engulfed by THP1.

[0055] Figure 4 : Anti-PLT antibodies cleaved by IdeS in vitro do not induce ITP. After a single injection (square), thrombocytopenic anti-PLT IgG (250μg / each mouse) induces ITP in BALB / c mice. Single-cleaved anti-PLT IgG (triangle) only partially induces ITP at the same dose, while anti-PLT IgG completely cleaved into F(ab')2 and Fc does not affect normal platelet levels. Mice received 0.25mg / each mouse of purified IgG in 200μl PBS intraperitoneally. Platelet counts were determined on day 1 using an automated cell counter VetScan HM5.

[0056] Figure 5 : In vivo IdeS treatment can prevent antibody-induced ITP. BALB / c mice were induced to ITP by a single ip injection of purified whole rabbit anti-mouse platelet IgG (0.25 mg / each mouse). One hour after induction of ITP, IdeS treatment was administered iv at three different doses (0.2, 2 and 20 μg / each mouse). The "PBS only" (circles) treatment group did not receive IdeS and only received anti-PLT-IgG as a positive control for ITP induction. Naive mice (diamonds) that received only vehicle solution represent the healthy control group. Platelet counts were determined on day 1 using an automated cell counter VetScan HM5.

[0057] Figure 6 : EndoS protects mice from ITP even after anti-PLT antibody injection. BALB / c mice (n=6 per group) were injected with 50 μg anti-PLT IgG to induce ITP, or injected with PBS alone (circles) as a control for normal platelet levels. 30 minutes later, EndoS therapeutic ip injections (10, 30 or 90 μg / mouse) were performed. ITP induction controls were injected with PBS (diamonds). Blood was drawn 24 hours later and platelet counts were analyzed using an automated cell counter VetScan HM5.

[0058] Figure 7: Identification of anti-CAR specific antibodies - F(ab')2 specific polyclonal antibodies specifically binding to CAR T cell receptors. The binding of polyclonal rabbit anti-mouse F(ab')2 antibodies (10μg / mL, 1μg / mL) to primary CAR T cells was evaluated, including: (A) anti-CD19 CAR T cells; and (B) anti-BCMA4 CAR T cells; and (C) mock-transfected T cells; and (D) Daudi cells expressing BCR, which served as negative and positive controls, respectively. The bound anti-F(ab')2 antibodies were detected by flow cytometry analysis using biotinylated anti-rabbit Fc and SA-AF647. Similarly, the binding of polyclonal rabbit anti-mouse F(ab')2 and anti-human F(ab')2 (10μg / mL) was also evaluated by FACS analysis using the anti-CD19 CAR-Jurkat T cell line (E) (CARJ-ZP005, Creative biolabs), expressed as MFI.

[0059] Figure 8: Identification of HAMA and anti-CD19 CAR Jurkat T cell allogeneic specific sera. (A) Normal human serum samples (BioIVT) were screened for human anti-mouse IgG antibodies (HAMA) using a validated sandwich ELISA kit (Biolegend). The threshold for HAMA-positive sera was set to >10 ng / mL. (B) ELISA-screened HAMA sera were incubated with anti-CD19-CAR-Jurkat T cells. Jurkat wt cells were used as CAR-negative staining controls. After incubation with PE-conjugated goat anti-human Fc detection antibodies, cells were analyzed by flow cytometry. (C) HAMA-positive and negative sera were selected and further tested for specific binding to anti-CD19 CAR-Jurkat T cells by flow cytometric analysis. These sera were further used to detect IgG effector mechanisms together with anti-CD19 CAR-Jurkat T cells. (D) Sera from HLA-sensitized patients were screened for alloreactivity against anti-CD19 CAR-Jurkat T cells. Sera from OneLambda were used as HLA class I positive and negative controls.

[0060] Fig. 9: Imlifidase treatment prevents CAR-specific antibody-induced ADCP - Imlifidase treatment prevents ADCP opsonization of polyclonal anti-F(ab')2 antibodies against CD19 CAR-Jurkat T cells. For flow cytometry-based ADCP analysis, target cells (including (A, B) anti-CD19 CAR-Jurkat, (D, E) Jurkat wt cells, and (C, F) Daudi cells expressing CD20 and BCR) were stained with calcein-AM and then incubated with the indicated concentrations of imlifidase-treated rabbit (A, C, D) anti-mouse F(ab')2 or (B, E, F) anti-human F(ab')2. The mononuclear phagocytic effector cell line THP-1 was stained with CellTrace FarRed and then added to the target cells for 90 minutes. Phagocytosis was assessed by flow cytometry. The amount of double-positive cells (which reflects the engulfed target cells) is expressed as a percentage of the target cells.

[0061] Fig.10 : Imlifidase prevents allogeneic serum-opsonized anti-CD19 CAR-Jurkat T cells from inducing ADCP. Target anti-CD19–CAR-Jurkat cells were opsonized with sera from (A) healthy donors and (B) highly sensitized anti-HLA patients with or without imlifidase (10 μg / mL) treatment. After washing, target cells were incubated with FcγRI-expressing reporter cells at 37°C for 6 h to induce ADCP. Luciferase activity as a result of activated reporter cells was measured using a luminescence reader, where luminescence signals (RLU) were expressed as mean fold change ± SD of the induction value.

[0062] Fig.11: Imlifidase treatment prevents ADCC induced by anti-CD19 CAR-specific antibodies (V158). Anti-CD19 CAR-Jurkat T cells were opsonized with indicated concentrations of polyclonal rabbit (A) anti-mouse and (B) anti-human F(ab')2 specific antibodies in the presence or absence of imlifidase (20 μg / mL). Luciferase reporter bioassay using high-affinity FcγRIIIa (V158) transfected reporter cells (Promega, #G7015) was used to quantify the induction of ADCC. (C) CAR-negative Jurkatwt cells were treated with rabbit anti-human IgG F(ab')2 in the presence / absence of imlifidase. BCR and CD20-positive Daudi cells, representing positive target cell controls for ADCC induction by (D) rituximab and (E) anti-human F(ab')2 specific antibodies. The luminescent signal (RLU) derived from activated effector cells is expressed as the average fold change ± SD of the induction value (replicate).

[0063] Fig.12 :Imlifidase treatment prevents ADCC induced by anti-CD19 CAR-specific antibodies (F158). Anti-CD19 CAR-Jurkat T cells were conditioned with (A) polyclonal rabbit anti-mouse and (B) anti-human F(ab')2 specific antibodies at indicated concentrations in the presence or absence of Imlifidase (20 μg / mL). Luciferase reporter bioassay using low-affinity FcγRIIIa (F158) transfected reporter cells (Promega, #G979A) was used to quantify the induction of ADCC. (C) CAR-negative Jurkatwt cells were treated with rabbit anti-mouse IgG F(ab')2 in the presence / absence of Imlifidase. BCR and CD20-positive Daudi cells, representing positive target cell controls for ADCC induction by (D) rituximab and (E) anti-human F(ab')2 specific antibodies. The luminescent signal (RLU) derived from activated effector cells is expressed as the average fold change ± SD of the induction value (replicate).

[0064] Fig.13: ADCC induction by HAMA-opsonized anti-CD19 CAR-Jurkat T cells is prevented by imlifidase treatment. ADCC induction was determined using a reporter cell line expressing the CD16 FcγRIIIa high-affinity (V158) allele. The scFv-CD19-CAR Jurkat cell line based on the murine mAb FMC63 was incubated with normal human serum samples (previously tested for HAMA levels against murine IgG by ELISA) in the presence / absence of imlifidase, and HAMA-positive (184, 187, 208, 250) and HAMA-negative (164) human sera were included in the ADCC assay. The luminescence signal (RLU) derived from activated effector cells is expressed as mean (replicate) ± SD.

[0065] Fig.14 :Imlifidase treatment of serum improves binding of target CD19 protein to anti-CD19 CAR T cells——The binding of CD19 protein to anti-CD19 CAR T cells exposed to serum can be increased by imlifidase treatment. Anti-CD19 CAR-Jurkat T cells were incubated with HAMA-positive and negative serum samples with or without imlifidase (10μg / mL). In the next step, IHAc (1mM) was added to all samples to inactivate imlifidase. Serum samples were incubated with anti-CD19 CAR-Jurkat T cells to allow possible binding of each IgG F(ab')2 to the anti-CD19CAR. After washing, recombinant atto-647N-labeled human CD19-Fc protein (ATM9269, R&D systems) was added to the cells, and anti-CD19 CAR and CD19-target protein interactions were evaluated by flow cytometry. The results are expressed as median fluorescence intensity (FI).

[0066] Fig.15: In vitro co-culture of CAR-T cells targeting immunoglobulin light chains with soluble immunoglobulins shows abrogation of IFNγ production. T cells from two healthy human donors (BC170909 and BC170803) were transduced with CD19.CAR, κ.CD28, or not transduced (NTD). NTD and CD19.CAR served as negative controls, and both cell types were expected to not produce IFNγ when inoculated with soluble immunoglobulins. They were then inoculated in serum with varying concentrations of soluble immunoglobulins, ranging from no soluble immunoglobulins (labeled TCM) to 10%, 50%, or 90% soluble immunoglobulins in serum, in the presence or absence of IdeS. Supernatants of co-cultures were collected 24 hours after inoculation, and IFNγ concentrations were measured by ELISA. As expected, NTD and CD19.CAR did not produce IFNγ under any inoculation conditions. In the presence of soluble immunoglobulins, κ.CD28 (labeled K28 in the figure) did produce increasing amounts of IFNγ. However, when IdeS was added to the co-culture, the ability of κ.CD28 to produce IFNγ was abolished, as shown on the right side of the figure. In each set of bars, the bars from left to right show NTD, CD19, and K28.

[0067] Figure 16: Inhibited IFNγ production was found within the κ.CAR. T cells from another healthy donor were transduced with CD19.CAR, κ.CD28, a CAR construct targeting λ light chain (λ.CD28), and NTD. When vaccinated with increasing concentrations of soluble immunoglobulin, κ.CD28 continued to show IFNγ production, while in the presence of IdeS, IFNγ production was reduced. The λ.CD28 CAR construct did not show significant differences in the presence or absence of the IdeS molecule. This may be due to the polyclonal nature of the soluble immunoglobulin serum used in the co-culture, and the proportion of λ light chains may be below the threshold required to activate λ.CD28CAR T cells. Fig.16A In each group of bars, the bars from left to right show NTD 1E6, NTD 2E6, NTD 3E6. Fig. 16B In each set of bars, the bars from left to right show CD19.CD28z 1E6, CD19.CD28z 2E6, CD19.CD28z 3E6. Fig. 16C In each group of bars, the bars from left to right show κ.CD28 1E6, κ.CD28 2E6, κ.CD28 3E6. Fig.16D In each group of bars, the bars from left to right show λ.CD28 1E6, λ.CD28 2E6, λ.CD28 3E6.

[0068] A brief description of the sequence

[0069] SEQ ID NO: 1 is the complete sequence of IdeS, including the N-terminal methionine and the signal sequence. It can also be obtained from NCBI under reference number WP_010922160.1.

[0070] SEQ ID NO: 2 is the mature sequence of IdeS, lacking the N-terminal methionine and signal sequence. It is also available as Genbank accession number ADF13949.1.

[0071] SEQ ID NO: 3 is the complete sequence of IdeZ, including the N-terminal methionine and the signal sequence. It can also be obtained from NCBI under reference number WP_014622780.1.

[0072] SEQ ID NO: 4 is the mature sequence of IdeZ lacking the N-terminal methionine and signal sequence.

[0073] SEQ ID NO: 5 is the sequence of the hybrid IdeS / Z. The N-terminus is based on IdeZ lacking the N-terminal methionine and signal sequence.

[0074] SEQ ID NOs: 6-25 are sequences of exemplary proteases used in the methods of the invention.

[0075] SEQ ID NO: 26 is the sequence of the IdeS polypeptide. It comprises the sequence of SEQ ID NO: 2 with an additional N-terminal methionine and histidine tag (internal reference pCAR T124).

[0076] SEQ ID NO: 27 is the sequence of the IdeZ polypeptide, comprising the sequence of SEQ ID NO: 4 with an additional N-terminal methionine and histidine tag (internal reference pCAR T144).

[0077] SEQ ID NO: 28 is the sequence of the IdeS / Z polypeptide. It comprises the sequence of SEQ ID NO: 5 with an additional N-terminal methionine and histidine tag (internal reference pCAR T145).

[0078] SEQ ID NO:29 is the consecutive sequence PLTPEQFRYNN, which corresponds to positions 63-73 of SEQ ID NO:3.

[0079] SEQ ID NO:30 is the consecutive sequence PPANFTQG, which corresponds to positions 58-65 of SEQ ID NO:1.

[0080] SEQ ID NO:31 is the consecutive sequence DDYQRNATEAYAKEVPHQIT, which corresponds to positions 35-54 of SEQ ID NO:3.

[0081] SEQ ID NO:32 is the consecutive sequence DSFSANQEIRYSEVTPYHVT, which corresponds to positions 30-49 of SEQ ID NO:1.

[0082] SEQ ID NOs: 33-55 are nucleotide sequences encoding the above-mentioned proteases.

[0083] SEQ ID NOs: 56-69 are sequences of exemplary proteases useful in the methods of the invention.

[0084] SEQ ID NO:70 is the consecutive sequence NQTN, which corresponds to positions 336-339 of SEQ ID NO:1.

[0085] SEQ ID NO:71 is the consecutive sequence DSFSANQEIR YSEVTPYHVT, which corresponds to positions 30-49 of SEQ ID NO:1.

[0086] SEQ ID NOs: 72-86 are nucleotide sequences encoding the polypeptides disclosed herein.

[0087] SEQ ID NO:87 is the sequence SFSANQEIRY SEVTPYHVT, which corresponds to positions 31-49 of SEQ ID NO:1.

[0088] SEQ ID NO: 88 is the sequence DYQRNATEAY AKEVPHQIT, which corresponds to positions 36-54 of the IdeZ polypeptide (NCBI Reference Sequence No. WP_014622780.1).

[0089] SEQ ID NO: 89 is the sequence DDYQRNATEAYAKEVPHQIT, which may be present at the N-terminus of a polypeptide of the present invention.

[0090] The amino acid sequence of mature endoglycosidase S (EndoS) is shown in SEQ ID NO: 90. The complete sequence including the secretion signal is available at Genbank Accession No. AAK00850.1.

[0091] SEQ ID NO: 91 represents a polypeptide having IgG cysteine ​​protease activity, wherein the polypeptide cleaves human IgG more efficiently than IdeZ.

[0092] SEQ ID NO:92 is related to SEQ ID NO:91 and is identical to SEQ ID NO:91 except that the first 20 amino acids at the N-terminus of SEQ ID NO:91 are deleted. DETAILED DESCRIPTION

[0093] Methods to improve the benefits of adoptive cell transfer immunotherapy for patients

[0094] The present invention provides a method for improving the benefits of adoptive cell transfer immunotherapy targeting immunoglobulin light chains to patients, the method comprising administering a protein having IgG cysteine ​​protease or IgG endoglycosidase activity in combination with adoptive cell transfer immunotherapy. The inventors have determined that immunoglobulins in plasma may be bound by transfer cells targeting immunoglobulin light chains, thereby causing exhaustion and possibly blocking the interaction between transfer cells and their targets on tumors. The inventors have demonstrated that proteins having IgG cysteine ​​protease or IgG endoglycosidase activity can cleave immunoglobulins in plasma, helping to maintain the anti-cancer activity of transfer therapeutic cells. Therefore, administering a protein having IgG cysteine ​​protease or IgG endoglycosidase activity can increase or maintain the activity of adoptive cell transfer immunotherapy targeting immunoglobulin light chains.

[0095] The inventors have also determined that the efficacy of adoptive cell transfer immunotherapy may be reduced due to the limited survival and limited sustained activity of transferred cells (such as CAR-T cells), and the inventors have shown in the embodiments that proteins with IgG cysteine ​​protease or IgG endoglycosidase activity can protect transferred cells. In particular, the inventors have confirmed that cell surface receptor-specific antibodies can reduce the potential of transferred cells, and the therapeutic effect of transferred cells will benefit from the removal of antibody effector functions by regulating the recipient. Similarly, the soluble antibodies combined with adoptive cell transfer immunotherapy targeting immunoglobulin light chains may also reduce the potential of transferred cells. Therefore, the application of proteins with IgG cysteine ​​protease or IgG endoglycosidase activity can improve the survival and activity of transferred cells and provide improved treatment. The inventors have also demonstrated that cell surface receptor-specific antibodies can interfere with the binding of adoptive cell transfer immunotherapy receptors to their targets. Therefore, the application of proteins with IgG cysteine ​​protease or IgG endoglycosidase activity can increase the efficacy and effect of adoptive cell transfer immunotherapy.

[0096] In certain embodiments, the present invention provides a method for maintaining or increasing the activity of cells administered as part of adoptive cell transfer targeting immunoglobulin light chains, the method comprising administering a protein having IgG cysteine ​​protease or IgG endoglycosidase activity before, after, or simultaneously with the adoptive cell transfer immunotherapy. In certain embodiments, the present invention provides a method for extending the survival and / or enhancing the proliferation of cells administered as part of adoptive cell transfer, the method comprising administering a protein having IgG cysteine ​​protease or IgG endoglycosidase activity before, after, or simultaneously with the adoptive cell transfer immunotherapy.

[0097] In certain embodiments, the invention provides a method of conditioning or preparing a patient for adoptive cell transfer immunotherapy targeting immunoglobulin light chains, the method comprising administering a protein having IgG cysteine ​​protease or IgG endoglycosidase activity.

[0098] In certain embodiments, the invention provides a method of reducing plasma IgG levels or reducing complement or Fc receptor binding to plasma IgG molecules in a patient undergoing or planning to undergo adoptive cell transfer immunotherapy targeting immunoglobulin light chains.

[0099] In certain embodiments, the present invention provides a method for increasing the efficacy of adoptive cell transfer therapy targeting immunoglobulin light chains, the method comprising administering a protein having IgG cysteine ​​protease or IgG endoglycosidase activity before, after, or simultaneously with the adoptive cell transfer immunotherapy. In certain embodiments, the present invention provides a method for increasing the binding between a cell surface receptor and its target for adoptive cell transfer therapy, the method comprising administering a protein having IgG cysteine ​​protease or IgG endoglycosidase activity before, after, or simultaneously with the adoptive cell transfer immunotherapy.

[0100] In certain embodiments, the method for improving the benefits of adoptive cell transfer immunotherapy targeting immunoglobulin light chains to patients includes administering a protein with IgG cysteine ​​protease or IgG endoglycosidase activity and subsequently administering adoptive cell transfer immunotherapy. Such methods will cause the immunoglobulins present in the plasma to be removed and / or inactivated, and pre-existing anti-drug antibodies (ADA) to be inactivated by proteins before administering cells, which will cause cells to have better activity, expansion and survival. ADA can be combined with any part of any cell therapy, including expressed CAR or TCR or HLA antigens (particularly in allogeneic therapy). These embodiments show that proteins such as IdeS are effective for removing antibodies that stimulate or block CAR-T cells targeting immunoglobulin light chains. The embodiment also shows that IdeS and EndoS can effectively inactivate pre-existing antibodies, for example, it is effective to use IdeS and EndoS before adding complement sources or effector cells. The embodiments also show that antibodies present in the serum of healthy individuals and HLA sensitized patients who have not been administered adoptive cell transfer immunotherapy can bind to receptor constructs and cells such as CAR T cells and mediate harmful effects (such as ADCP, ADCC and interference with target binding), all of which can be reduced by treating with the protein of the present invention. The present invention also provides a protein with IgG cysteine ​​protease or IgG endoglycosidase activity for regulating the patient by adoptive cell transfer immunotherapy targeting immunoglobulin light chains. The present invention also provides a protein with IgG cysteine ​​protease or IgG endoglycosidase activity for reducing the plasma IgG level of patients who are planned to receive adoptive cell transfer immunotherapy targeting immunoglobulin light chains. The present invention also provides a protein with IgG cysteine ​​protease or IgG endoglycosidase activity for reducing the plasma IgG level of patients who have previously provided blood for the development of adoptive cell transfer immunotherapy targeting immunoglobulin light chains but have not yet received adoptive cell transfer immunotherapy targeting immunoglobulin light chains. The present invention also provides an adoptive cell transfer immunotherapy composition targeting immunoglobulin light chain for treating patients who have previously received administration of a protein having IgG cysteine ​​protease or IgG endoglycosidase activity.

[0101] In a preferred embodiment, a method for improving the benefits of adoptive cell transfer immunotherapy to a patient comprises administering a protein having IgG cysteine ​​protease or IgG endoglycosidase activity before administering the adoptive cell transfer immunotherapy. Such methods will allow soluble plasma immunoglobulins to be cleaved so that they cannot stimulate and exhaust or block immunoglobulin light chain-specific cells. Therefore, the activity of the transferred cells will be improved. The present invention also provides a protein having IgG cysteine ​​protease or IgG endoglycosidase activity for improving the benefits of adoptive cell transfer immunotherapy planned for the patient. The present invention also provides a protein having IgG cysteine ​​protease or IgG endoglycosidase activity for treating patients planned to receive adoptive cell transfer immunotherapy. The present invention also provides a protein having IgG cysteine ​​protease or IgG endoglycosidase activity for reducing the plasma IgG level of patients planned to receive adoptive cell transfer immunotherapy. The present invention also provides an adoptive cell transfer immunotherapy composition for treating patients who have previously received the administration of a protein having IgG cysteine ​​protease or IgG endoglycosidase activity.

[0102] In certain embodiments, a method for improving the benefits of adoptive cell transfer immunotherapy to a patient comprises administering a protein having IgG cysteine ​​protease or IgG endoglycosidase activity after administering adoptive cell transfer immunotherapy. Such methods will inactivate pre-existing anti-drug antibodies (ADA) and antibodies caused by adoptive cell transfer immunotherapy. Such methods can also inactivate soluble antibodies that may have been bound by transferred cells. The expansion and survival of transferred cells will therefore be improved. The examples show that IdeS and EndoS can effectively inactivate harmful polyclonal antibodies and induced antibodies because immune thrombocytopenia is reduced when Ides and EndoS are administered after anti-platelet-specific antibodies. The present invention also provides a protein having IgG cysteine ​​protease or IgG endoglycosidase activity for improving the benefits of previously administered adoptive cell transfer immunotherapy to a patient. The present invention also provides a protein having IgG cysteine ​​protease or IgG endoglycosidase activity for treating patients who have previously received adoptive cell transfer immunotherapy. The present invention also provides a protein having IgG cysteine ​​protease or IgG endoglycosidase activity for reducing the plasma IgG level of a patient previously treated with adoptive cell transfer immunotherapy. The present invention also provides an adoptive cell transfer immunotherapy composition for treating a patient who is scheduled to receive administration of a protein having IgG cysteine ​​protease or IgG endoglycosidase activity.

[0103] In a further embodiment, a method of improving the benefit of adoptive cell transfer immunotherapy to a patient comprises administering a protein having IgG cysteine ​​protease or IgG endoglycosidase activity both before and after the administration of the adoptive cell transfer immunotherapy dose. Such methods will inactivate pre-existing anti-drug antibodies (ADA) and antibodies caused by adoptive cell transfer immunotherapy. Such methods may also inactivate soluble antibodies that may have been bound by the transferred cells. The expansion and survival of the transferred cells will therefore be improved.

[0104] In a further embodiment, the method for improving the benefits of adoptive cell transfer immunotherapy to patients includes administering a protein having IgG cysteine ​​protease or IgG endoglycosidase activity after administering the first adoptive cell transfer immunotherapy and before administering the second adoptive cell transfer immunotherapy. Therefore, the protein is administered between two or more doses of adoptive cell transfer immunotherapy. This method will allow the transferred cells to expand and survive better because any ADA from the previous injection will be inactivated. Such methods can also inactivate soluble antibodies that may have been bound by the transferred cells. In addition, soluble antibodies that may exhaust or block the transferred cells are removed or inactivated. Preferably, in such embodiments, the first and second and any subsequent adoptive cell transfer immunotherapy use the same or similar constructs and cells. In such embodiments, similar constructs or cells may have ADA cross-reactive epitopes. The present invention also provides a protein having IgG cysteine ​​protease or IgG endoglycosidase activity for treating patients who have previously received a first dose of adoptive cell transfer immunotherapy and plan to receive a second dose of adoptive cell transfer immunotherapy. The present invention also provides a protein having IgG cysteine ​​protease or IgG endoglycosidase activity for reducing IgG levels in patients undergoing a multiple-dose regimen of adoptive cell transfer immunotherapy. The present invention also provides a protein having IgG cysteine ​​protease or IgG endoglycosidase activity for increasing the benefit of a multiple-dose regimen of adoptive cell transfer immunotherapy treatment to a patient. The present invention also provides an adoptive cell transfer immunotherapy composition for treating a patient who has previously received a dose of an adoptive cell transfer immunotherapy composition and has previously received administration of a protein having IgG cysteine ​​protease or IgG endoglycosidase activity.

[0105] In a further embodiment, a method for improving the benefits of adoptive cell transfer immunotherapy to a patient comprises administering a protein having IgG cysteine ​​protease or IgG endoglycosidase activity after administering two or more doses of adoptive cell transfer immunotherapy. Such methods will inactivate antibodies caused by adoptive cell transfer immunotherapy. Such methods can also inactivate soluble antibodies that may have been bound by transferred cells. In addition, soluble antibodies that may exhaust or block transferred cells are removed or inactivated. The expansion and survival of transferred cells will therefore be improved. The present invention also provides a protein having IgG cysteine ​​protease or IgG endoglycosidase activity for improving the benefits of adoptive cell transfer immunotherapy previously administered in two or more doses to a patient. The present invention also provides a protein having IgG cysteine ​​protease or IgG endoglycosidase activity for treating patients who have previously received two or more doses of adoptive cell transfer immunotherapy. The present invention also provides a protein having IgG cysteine ​​protease or IgG endoglycosidase activity for reducing the plasma IgG level of patients who have previously received two or more doses of adoptive cell transfer immunotherapy.

[0106] In certain embodiments of the invention, methods for improving the benefits of adoptive cell transfer immunotherapy to patients include multiple administrations of proteins with IgG cysteine ​​protease or IgG endoglycosidase activity and multiple administrations of adoptive cell transfer immunotherapy. In certain embodiments, multiple administrations of proteins with IgG cysteine ​​protease or IgG endoglycosidase activity include administration of the same enzyme. Repeated doses of proteins with IgG cysteine ​​protease or IgG endoglycosidase activity can be spaced at any suitable time period, such as 1-7 days, 5-7 days or 6-8 days. In certain embodiments, multiple administrations of proteins with IgG cysteine ​​protease or IgG endoglycosidase activity include administration of different enzymes.

[0107] In certain embodiments of the invention, a method for improving the benefit of adoptive cell transfer immunotherapy to a patient comprises administering a protein having IgG cysteine ​​protease or IgG endoglycosidase activity simultaneously with the adoptive cell transfer immunotherapy. The examples show that cell surface receptor-specific antibodies can interfere with the binding of the adoptive cell transfer immunotherapy receptor to its target, but the binding can be increased by treatment with the protein of the invention, so that the efficacy and effect of adoptive cell transfer immunotherapy can be improved by administering a protein having IgG cysteine ​​protease or IgG endoglycosidase activity simultaneously.

[0108] Administration of a protein having IgG cysteine ​​protease or IgG endoglycosidase activity will reduce the stability, half-life and Fc effector function of plasma IgG immunoglobulins, thereby reducing their deleterious effects on immunotherapy cells. In addition, cleavage of IgG immunoglobulins can prevent crosslinking between immunotherapy cells and FcgR, which otherwise may lead to extra-tumor activation and exhaustion. In a preferred embodiment of the method of the present invention, administration of a protein having IgG cysteine ​​protease or IgG endoglycosidase activity will cleave all or nearly all IgG molecules present in the patient's plasma.

[0109] In a preferred embodiment of the method of the invention, the protein having IgG cysteine ​​protease or IgG endoglycosidase activity is administered to inactivate all or substantially all IgG molecules present in the patient's plasma. In certain embodiments, the protein is administered in an amount sufficient to eliminate binding of Fc receptors or complement to all or substantially all IgG molecules present in the patient's plasma.

[0110] In certain embodiments of the methods of the present invention, the use of proteins with IgG cysteine ​​protease or IgG endoglycosidase activity can remove or inactivate antibodies in the blood. In certain embodiments, antibodies in the lymph are also inactivated. In certain embodiments, antibodies in the interstitial fluid are also inactivated. Therefore, removing or inactivating antibodies from plasma according to the present invention can include removing or inactivating antibodies from lymph and / or interstitial fluid. Removing or inactivating antibodies in lymph and / or interstitial fluid will delay the replenishment of plasma antibodies, thereby reducing the negative impact of plasma antibodies on metastatic cells for a longer period of time.

[0111] In the method of the present invention wherein the protein with IgG cysteine ​​protease or IgG endoglycosidase activity is administered before the adoptive cell transfer immunotherapy dose, the two administrations are separated by a time interval preferably sufficient to cut all or substantially all IgG molecules in the plasma of the subject. The interval can generally be at least 30 minutes and can generally be up to 21 days. The administration of the protein with IgG cysteine ​​protease or IgG endoglycosidase activity can occur simultaneously with lymphocyte clearance (e.g., on the same day), or 1-7 days before or after lymphocyte clearance. In certain embodiments, the administration of the protein occurs between lymphocyte clearance and the administration of cell therapy. "Substantially all" generally refers to that the binding of Fc receptors and complement to plasma IgG is reduced to 30%, 20%, 15%, 10% or 5% below the level present before administration. For example, if the protein is a protease (such as IdeS), the interval will be the time required for the reagent to cut at least 70%, 80%, 85%, 90% or 95% of the plasma IgG in the subject, as measured in the subject by any suitable assay, as measured by any suitable assay.

[0112] In the methods of the invention wherein a protein having IgG cysteine ​​protease or IgG endoglycosidase activity is administered after an adoptive cell transfer immunotherapy dose, the protein is preferably administered during proliferation of the transferred cells, e.g., within 2 weeks, within 1 week, within 2 days, within 1 day, or within 5 hours of administering the adoptive cell transfer immunotherapy.

[0113] In a preferred embodiment, the method of the present invention is used to reduce antibody-mediated complement deposition, CDC, ADCC, ADCP, exhaustion or receptor-activated cell death of cells previously administered to a patient in adoptive cell transfer immunotherapy. In a preferred embodiment, the method of the present invention is used to reduce antibody-mediated complement deposition, CDC, ADCC, ADCP, exhaustion or receptor-activated cell death of cells subsequently administered to a patient in adoptive cell transfer immunotherapy. In a preferred embodiment, the present invention provides a protein having IgG cysteine ​​protease or IgG endoglycosidase activity for reducing antibody-mediated complement deposition, CDC, ADCC, ADCP, exhaustion or receptor-activated cell death of cells previously administered to a patient in adoptive cell transfer immunotherapy. In other preferred embodiments, the present invention provides a protein having IgG cysteine ​​protease or IgG endoglycosidase activity for reducing antibody-mediated complement deposition, CDC, ADCC, ADCP, exhaustion or receptor-activated cell death of cells subsequently administered to a patient in adoptive cell transfer immunotherapy. In a preferred embodiment, ADCC is mediated by FcγRIIIa(V158) effector cells or FcγRIIIa(F158) effector cells.

[0114] In certain embodiments, the method of the present invention comprises administering a protein having IgG cysteine ​​protease or IgG endoglycosidase activity to a patient with a detectable level of human anti-mouse antibodies (HAMA), HAMA being an immunoglobulin specific for mouse immunoglobulin. The administration can be performed before, after, or simultaneously with the administration of adoptive cell transfer immunotherapy. The embodiments show that HAMA in patient serum can have a deleterious effect on adoptive cell transfer immunotherapy cells, but these effects can be reduced or prevented by treatment with the protein of the present invention. HAMA can be induced in normal individuals by contact with mouse antigens. The frequency and concentration of HAMA are expected to be higher in patients receiving mouse mAb-based biologics, and in some cases may even result in partial neutralization of these therapeutic agents.

[0115] In the method of the present invention, IgG cysteine ​​protease or IgG endoglycosidase can be co-administered with immunosuppressants. In the method of the present invention, the protease is preferably administered by intravenous infusion, but can also be administered by any suitable route, including, for example, intradermal, subcutaneous, percutaneous, intramuscular, intraarterial, intraperitoneal, intraarticular, intraosseous, intrathecal, intraventricular or other suitable administration routes. The amount of the protease or endoglycosidase administered can be 0.01 mg / kg BW to 2 mg / kg BW, 0.05 to 1.5 mg / kg BW, 0.1 mg / kg BW to 1 mg / kg BW, preferably 0.15 mg / kg BW to 0.7 mg / kg BW, most preferably 0.2 mg / kg BW to 0.3 mg / kg BW, particularly 0.25 mg / kg BW. The protein can be administered to the same subject multiple times, provided that the amount of anti-drug antibodies (ADA) in the subject's plasma that can bind to the protein does not exceed the threshold value determined by the clinician. The amount of ADA in the subject's plasma that is capable of binding to a protease can be determined by any suitable method, such as an agent-specific CAP EIA (ImmunoCAP) test or a titer assay.

[0116] Methods of treating cancer

[0117] The present invention provides a method for treating cancer, which comprises administering a protein having IgG cysteine ​​protease or IgG endoglycosidase activity in combination with adoptive cell transfer immunotherapy targeting immunoglobulin light chains. The reduction in cytokine production and stimulation in the presence of soluble immunoglobulins shown in the examples indicates that administration of a protein having IgG cysteine ​​protease or IgG endoglycosidase activity can reduce exhaustion and increase the activity of transferred cells and provide improved cancer treatment. In addition, the protection of cells shown in the examples indicates that administration of a protein having IgG cysteine ​​protease or IgG endoglycosidase activity can increase the survival and activity of transferred cells and provide improved cancer treatment.

[0118] In a preferred embodiment, the method for treating cancer comprises administering a protein having IgG cysteine ​​protease or IgG endoglycosidase activity and subsequently administering adoptive cell transfer immunotherapy targeting immunoglobulin light chains. The present invention also provides a protein having IgG cysteine ​​protease or IgG endoglycosidase activity for regulating cancer treatment for patients by adoptive cell transfer immunotherapy targeting immunoglobulin light chains. The present invention also provides a protein having IgG cysteine ​​protease or IgG endoglycosidase activity for reducing the plasma IgG level of a patient who is scheduled to receive adoptive cell transfer immunotherapy cancer treatment. The present invention also provides a protein having IgG cysteine ​​protease or IgG endoglycosidase activity for reducing the plasma IgG level of a patient who previously provided blood for the development of adoptive cell transfer immunotherapy targeting immunoglobulin light chains but has not yet received adoptive cell transfer immunotherapy targeting immunoglobulin light chains. The present invention also provides an adoptive cell transfer immunotherapy composition targeting immunoglobulin light chains for treating cancer in a patient who has previously received administration of a protein having IgG cysteine ​​protease or IgG endoglycosidase activity.

[0119] In certain embodiments, the method of treating cancer comprises administering a protein having IgG cysteine ​​protease or IgG endoglycosidase activity after administering adoptive cell transfer immunotherapy. The present invention also provides a protein having IgG cysteine ​​protease or IgG endoglycosidase activity for increasing the benefit of a previously administered adoptive cell transfer immunotherapy to a patient. The present invention also provides a protein having IgG cysteine ​​protease or IgG endoglycosidase activity for treating cancer in a patient who has previously received adoptive cell transfer immunotherapy. The present invention also provides a protein having IgG cysteine ​​protease or IgG endoglycosidase activity for reducing plasma IgG levels in a patient who has previously received adoptive cell transfer immunotherapy cancer treatment. The present invention also provides an adoptive cell transfer immunotherapy composition for treating cancer in a patient who is scheduled to receive administration of a protein having IgG cysteine ​​protease or IgG endoglycosidase activity.

[0120] In a further embodiment, the method of treating cancer comprises administering a protein having IgG cysteine ​​protease or IgG endoglycosidase activity both before and after administering the adoptive cell transfer immunotherapy dose.

[0121] In a further embodiment, the method for treating cancer comprises administering a protein having IgG cysteine ​​protease or IgG endoglycosidase activity after administering a first adoptive cell transfer immunotherapy and before administering a second adoptive cell transfer immunotherapy. Preferably, in such embodiments, the first and second and any subsequent adoptive cell transfer immunotherapy use the same or similar constructs and cells. The present invention also provides a protein having IgG cysteine ​​protease or IgG endoglycosidase activity for treating cancer in patients who have previously received a first dose of adoptive cell transfer immunotherapy and are scheduled to receive a second dose of adoptive cell transfer immunotherapy. The present invention also provides a protein having IgG cysteine ​​protease or IgG endoglycosidase activity for reducing IgG levels in patients who are subjected to a multiple-dose regimen of adoptive cell transfer immunotherapy. The present invention also provides a protein having IgG cysteine ​​protease or IgG endoglycosidase activity for improving the benefits of multiple-dose regimen adoptive cell transfer immune cancer therapy treatment to patients. The present invention also provides an adoptive cell transfer immunotherapy composition for treating cancer in a patient who has previously received a dose of the adoptive cell transfer immunotherapy composition and has previously received administration of a protein having IgG cysteine ​​protease or IgG endoglycosidase activity.

[0122] In a further embodiment, the method of treating cancer comprises administering a protein having IgG cysteine ​​protease or IgG endoglycosidase activity after administering two or more doses of adoptive cell transfer immunotherapy. The present invention also provides a protein having IgG cysteine ​​protease or IgG endoglycosidase activity for increasing the benefit of adoptive cell transfer immunotherapy previously administered in two or more doses to a patient. The present invention also provides a protein having IgG cysteine ​​protease or IgG endoglycosidase activity for treating cancer in a patient who has previously received two or more doses of adoptive cell transfer immunotherapy. The present invention also provides a protein having IgG cysteine ​​protease or IgG endoglycosidase activity for reducing plasma IgG levels in a patient who has previously received two or more doses of adoptive cell transfer immunotherapy cancer treatment.

[0123] In certain embodiments of the invention, the method of treating cancer comprises multiple administrations of a protein having IgG cysteine ​​protease or IgG endoglycosidase activity and multiple administrations of adoptive cell transfer immunotherapy.

[0124] In certain embodiments of the invention, the method of treating cancer comprises concurrently administering a protein having IgG cysteine ​​protease or IgG endoglycosidase activity and adoptive cell transfer immunotherapy.

[0125] In the therapeutic methods of the present invention, proteins and adoptive cell transfer immunotherapy are administered to subjects already suffering from cancer in an amount sufficient to cure, alleviate, or partially arrest the cancer or one or more symptoms thereof. Such therapeutic treatment may result in remission, stabilization, reduction in metastasis, or elimination of the cancer. An amount sufficient to achieve this is defined as a "therapeutically effective amount." The subject may have been identified as suffering from cancer and is suitable for adoptive cell transfer immunotherapy by any suitable means.

[0126] Adoptive cell transfer immunotherapy

[0127] The methods of the present invention provide increased benefits from adoptive cell transfer (ACT) immunotherapy and thereby provide improved methods for treating cancer and other diseases such as antibody-mediated autoimmune diseases. ACT immunotherapy is an established and effective method for specifically treating cancer. ACT is the passive transfer of ex vivo grown cells (most commonly immune-derived cells) into a host with the goal of transferring the immune functions and characteristics of the transplant.

[0128] The ACT immunotherapy used according to the present invention targets immunoglobulin light chains. The immunoglobulin light chain may be a kappa light chain or a lambda light chain. Preferably, the immunoglobulin light chain is a human immunoglobulin light chain. ACT immunotherapy binds to immunoglobulin light chains by expressing a receptor construct (e.g., a chimeric antigen receptor (CAR) or a T cell receptor (TCR)), which comprises a binding domain (e.g., scFv) that specifically binds to an immunoglobulin light chain. Exemplary antibodies targeting human immunoglobulin kappa light chains are produced by CRL-1758 (ATCC) hybridomas. Exemplary antibodies targeting human immunoglobulin lambda light chains are produced by HP6054 (ATCC) hybridomas. Other antibodies targeting kappa light chains and lambda light chains are also readily available. ScFv or alternative constructs that bind to kappa light chains or lambda light chains of human immunoglobulins can be easily generated using the variable regions of these antibodies.

[0129] The ACT can be autologous (e.g., isolated by leukapheresis, transduced and selected approximately 4 weeks prior to administration), as is common in adoptive T cell therapy, or the ACT can be allogeneic, in which case the methods of the invention can improve the ACT by removing antibodies that recognize receptors and / or other antigens expressed on allogeneic cells. In addition, the ACT can be xenogeneic. In a preferred embodiment, the ACT is autologous.

[0130] ACT can also include the transfer of autologous tumor-infiltrating lymphocytes (TILs), which can be used to treat patients with advanced solid tumors (e.g., melanoma) and hematological malignancies.

[0131] ACT may also include the transfer of allogeneic lymphocytes isolated, prepared, and stored (eg, frozen) "off-the-shelf" from healthy donors, which may be used to treat patients with advanced solid tumors (eg, melanoma) and hematological malignancies.

[0132] The adoptive cellular immunotherapy of the present invention may include administering cells expressing chimeric antigen receptors (CAR) or T cell receptors (TCR), or may include tumor infiltrating lymphocytes (TIL). Cell groups expressing CAR / TCRs that recognize antigens may include activated T cell groups or natural killer (NK) cell groups or dendritic cell groups. Dendritic cells are capable of presenting antigens, and directly killing tumors. Dendritic cells may express, for example, anti-κ CAR or anti-λ CAR. Cell groups expressing CAR / TCRs may include gene-edited cell groups.

[0133] ACT can use cell types such as T cells, natural killer (NK) cells, delta-gamma T cells, regulatory T cells, dendritic cells, and peripheral blood mononuclear cells. ACT can use monocytes with the goal of inducing differentiation into dendritic cells and / or macrophages after exposure to tumor antigens.

[0134] According to a preferred embodiment of the present invention, adoptive cell therapy can be CAR T cell therapy. CAR T cells can be engineered to target κ or λ light chains by engineering a desired antigen binding domain that specifically binds to κ or λ light chains expressed on cancer cells. In a preferred embodiment, cell therapy uses cells of hematopoietic origin. The examples demonstrate that the method of the present invention is particularly effective for cells of hematopoietic origin.

[0135] In a preferred embodiment, adoptive cell therapy (preferably CAR T cell therapy) uses cells targeting κ light chains or λ light chains. Exemplary CAR-T cells are described in Ranganathan et al., Clin Cancer Res, 2021 and Vera et al., Blood 2006; 108. Exemplary antibodies targeting human immunoglobulin κ light chains are produced by CRL-1758 (ATCC) hybridomas. Exemplary antibodies targeting human immunoglobulin λ light chains are produced by HP6054 (ATCC) hybridomas. Other antibodies targeting κ light chains and λ light chains are also readily available. ScFv or alternative constructs that bind to human immunoglobulin κ light chains or λ light chains can be easily generated using the variable regions of such antibodies, for example as described in Ranganathan et al., Clin Cancer Res, 2021 and Vera et al., Blood 2006; 108. The CAR-T constructs used in the present invention may include human IgG1CH 2-The CH3 region and hinge and the ζ chain of the TCR / CD3 complex, and an optional CD28 domain. The CAR-T construct for the present invention may include a human CD8a hinge and transmembrane domain and a CD28 co-stimulatory domain and an intracytoplasmic CD3z chain of the TCR / CD3 complex. Preferred adoptive cell transfer immunotherapy is CAR T cell therapy (e.g., autologous cell therapy and allogeneic cell therapy). Preferred is CAR T cell therapy for the treatment of hematological malignancies such as ALL, AML, NHL, DLBCL and CLL. Examples of approved CAR T cell therapies include, but are not limited to, those for the treatment of NHL and DLBCL. (tisagenlecleucel) and for the treatment of NHL (axicabtageneciloleucel).

[0136] According to certain aspects of the invention, the cell population expressing CAR / TCR or TIL can be autologous cells, allogeneic cells derived from another human donor, or xenogeneic cells derived from an animal of a different species.

[0137] According to certain aspects of the invention, a population of cells expressing CAR / TCR or TIL can be isolated by leukapheresis, transduced and selected approximately 4 weeks prior to administration, as in the case of autologous stem cells, or can be isolated from a healthy donor and prepared in advance and then stored, such as a frozen preparation, for use in one or more patients, as in so-called "off-the-shelf" allogeneic CAR-T stem cell therapies.

[0138] According to certain aspects of the present invention, the cell population expressing CAR / TCR may include an activated T cell population or a natural killer (NK) cell population or a dendritic cell population expressing a CAR / TCR recognizing an antigen. Dendritic cells can present antigens and directly kill tumors.

[0139] CAR T cells may include antigen binding domains that can target two or more different antigens (i.e., bispecific or bivalent, trispecific or trivalent, tetraspecific, etc.). Therefore, CAR T cells may include a first antigen binding domain that binds to a first antigen and a second antigen binding domain that binds to a second antigen (e.g., tandem CAR). For example, CAR T cells may include an immunoglobulin light chain binding domain and a CD19 or CD22 binding domain, so that immunoglobulin light chains and CD19 or CD22 can be recognized and bound. Or further, CAR T cells may include an immunoglobulin light chain binding domain and a CD20 binding domain and thus can recognize and bind immunoglobulin light chains and CD20.

[0140] Alternatively, each cell in the cell population or the entire cell population may contain more than one different CAR T cell (e.g., construct), wherein each CAR T cell construct may recognize a different antigen. For example, a CAR T cell population may target three antigens.

[0141] According to certain aspects of the present invention, cell populations, whether autologous or allogeneic, can be engineered using gene editing techniques, such as by CRISPR / cas9 (clustered regularly interspaced short palindromic repeats / CRISPR-associated protein 9), zinc finger nucleases (ZFNs) or transcription activator-like effector nucleases (TALENs). These techniques, which are recognized and practiced in the field of genetic engineering, can selectively edit, destroy or insert target sequences to modify the genome of cells of interest. Therefore, the isolated autologous or allogeneic cells for adoptive transfer implemented in the present invention can be edited to delete or replace known genes or sequences. For example, the T cell receptor (TCR) in an allogeneic T cell population can be deleted or replaced before or after CAR-T transduction as a means of eliminating graft-versus-host disease in recipient patients.

[0142] According to certain aspects of the invention, the cell population administered as adoptive cell transfer immunotherapy may include a population of T cells, NK cells or dendritic cells expressing CAR, wherein the CAR comprises an extracellular antibody or antibody fragment comprising a humanized anti-κ or λ light chain binding domain, a transmembrane domain and one or more cytoplasmic co-stimulatory signaling domains.

[0143] In certain embodiments of the present invention, the cell group used as adoptive cell transfer immunotherapy expresses T cell receptor (TCR). TCR is an antigen-specific molecule responsible for identifying antigen peptides presented in the major histocompatibility complex (MHC) product on the surface of antigen presenting cells or any nucleated cells (e.g., all cells of the human body, except red blood cells). In contrast, antibodies generally recognize soluble antigens or cell surface antigens, and do not need to present antigens by MHC. The system gives T cells the potential ability to recognize all intracellular antigen arrays (including viral proteins) expressed by cells through the TCR of T cells, which are processed into short peptides in cells, combined with intracellular MHC molecules, and delivered to the surface as peptide-MHC complexes. The system allows almost any exogenous protein (e.g., mutated cancer antigens or viral proteins) or abnormally expressed proteins as targets of T cells.

[0144] According to certain aspects of the present invention, the engineered CAR cells can be allogeneic cells from a healthy donor and can be further engineered to ablate or replace endogenous TCRs by gene editing techniques such as CRISPR / cas9, ZFN or TALEN, wherein the endogenous TCR is deleted to eliminate CAR-driven graft-versus-host disease.

[0145] According to some aspects of the present invention, autologous cells (e.g., T cells or NK cells or dendritic cells) can be collected from an object. These cells can be obtained from many sources, including peripheral blood mononuclear cells, bone marrow, lymph node tissue, cord blood, thymus tissue, tissue from infection site, ascites, pleural effusion, spleen tissue and tumor. According to some aspects of the present invention, allogeneic or xenogeneic cells separated from healthy donors can be used. When T cells, NK cells, dendritic cells or pluripotent stem cells are allogeneic or xenogeneic cells, many cell lines available in the art can be used.

[0146] Many techniques known to those skilled in the art can be used, such as Ficoll TM Separation to obtain cells from a blood unit collected from a subject. According to certain aspects of the present invention, cells from the circulating blood of an individual can be obtained by apheresis. Apheresis products typically contain lymphocytes, including T cells, B cells, monocytes, granulocytes, other nucleated white blood cells, red blood cells and platelets.

[0147] The combination of antibodies for surface markers specific to negative selection cells can be used to achieve enrichment of cell populations by negative selection. One method is to sort and / or select cells by negative magnetic immunoadhesion or flow cytometry, which uses a mixture of monoclonal antibodies for cell surface markers present on cells for negative selection. For example, in order to enrich CD4+ cells by negative selection, a mixture of monoclonal antibodies generally includes antibodies for CD14, CD20, CD11b, CD16, HLA-DR and CD8. According to certain aspects of the present invention, enrichment or positive selection of cell populations may be required. For example, the positive enrichment of regulatory T cells can use the positive selection of CD4+, CD25+, CD62Lhi, GITR+ and FoxP3+.

[0148] The collected cells can be engineered to express CAR or TCR by any of a variety of methods known in the art. In addition, the engineered cells can be amplified by any of a variety of methods known in the art. As described above, the CAR or TCR can be bispecific, trispecific, or tetraspecific; the CAR or TCR can include switches such as goCAR or goTCR, or safety switch CAR or TCR; the CAR or TCR can express immunomodulatory proteins, such as armored CAR or TCR.

[0149] According to certain aspects of the invention, collection of a blood sample or apheresis product from a subject may be performed at any time period before the expanded cells described herein may be needed. Thus, a source of cells to be engineered and expanded (or simply expanded in the case of TILs) may be collected at any necessary time point, and the desired cells (e.g., T cells, NK cells, dendritic cells, or TILs) may be isolated and frozen for later use in ACTs, such as those described herein.

[0150] According to certain aspects of the invention, a population of cells expressing CAR / TCR can be administered to a subject by dose fractionation, wherein a first percentage of the total dose is administered on the first day of treatment, a second percentage of the total dose is administered on a subsequent treatment day, and optionally, a third percentage of the total dose is administered on a further subsequent treatment day.

[0151] An exemplary total dose comprises 10 3 -10 11 cells / kg subject weight, e.g. 10 3 -10 10 cells / kg subject body weight, or 10 3 -10 9 cells / kg subject body weight, or 10 3 -10 8 cells / kg subject body weight, or 10 3 -10 7 cells / kg subject body weight, or 10 3 -10 6 cells / kg subject body weight, or 10 3 -10 5 cells / kg subject body weight. In addition, an exemplary total dose comprises 10 4 -10 11 cells / kg subject weight, e.g. 10 5 -10 11 cells / kg subject body weight, or 10 6 -10 11 cells / kg subject body weight, or 107 -10 11 cells / kg subject body weight.

[0152] An exemplary total dose may be administered based on the patient's body surface area rather than body weight. Thus, the total dose may include 10 3 -10 13 Cells / m 2 .

[0153] Exemplary doses can be based on a rigid or fixed dosing schedule rather than on body weight or body surface area. Rigid dosing can avoid potential dose calculation errors. In addition, genotyping and phenotyping strategies and therapeutic drug monitoring can be used to calculate appropriate doses. That is, administration can be based on the patient's immune repertoire of immunosuppressive cells (e.g., regulatory T cells, myeloid-derived suppressor cells) and / or disease burden. Thus, the total dose may include 10 3 -10 13 Total cells.

[0154] According to certain aspects of the present invention, cells can be obtained directly from the object after treatment. In this regard, it has been observed that after certain cancer treatments, particularly treatments with drugs that destroy the immune system, the quality of certain cells (e.g., T-cells) obtained may be optimal or improved in their ability to be amplified in vitro in the period when the object is usually recovered from treatment soon after treatment. Similarly, after using the methods described herein to perform in vitro operations, these cells may be in a preferred state for enhanced transplantation and in vivo amplification. Therefore, it is expected in the context of the present invention that blood cells, including T cells, NK cells, dendritic cells, or other cells of the hematopoietic lineage, are collected during this recovery phase.

[0155] According to certain aspects of the present invention, the second dose can be the same or different effective amounts of different cell populations expressing the same or different CAR / TCR. The differences in CAR / TCR can be in any aspect of CAR / TCR, such as different binding or antigen recognition domains or costimulatory domains. The second dose may additionally or alternatively include IL-12 secreting cells, or may even include adjuvant immunotherapy using small molecule inhibitors such as BTK, P13K, IDO inhibitors simultaneously or sequentially with cell therapy infusions.

[0156] According to certain aspects of the invention, in addition to adoptive cell transfer immunotherapy and IgG cysteine ​​protease or endoglycosidase, the method may also include administering one or more additional therapeutic agents. Exemplary therapeutic agents include chemotherapeutic agents, anti-inflammatory agents, immunosuppressants, immunomodulators, or combinations thereof.

[0157] The therapeutic agent can be administered according to any standard dosage regimen known in the art. Exemplary chemotherapeutic agents include antimitotic agents, such as taxanes, such as docetaxel and paclitaxel, and vinca alkaloids, such as vindesine, vincristine, vinblastine, and vinorelbine. Exemplary chemotherapeutic agents include topoisomerase inhibitors, such as topotecan.

[0158] Exemplary chemotherapeutic agents include growth factor inhibitors, tyrosine kinase inhibitors, histone deacetylase inhibitors, P38a MAP kinase inhibitors, angiogenesis, new blood vessel formation and / or other angiogenesis inhibitors, colony stimulating factors, erythropoiesis agents, anti-allergic agents, immunosuppressants and / or immunomodulators, viruses, viral proteins, immune checkpoint inhibitors, BCR inhibitors (e.g., BTK, P13K, etc.), immunometabolites (e.g., IDO, arginase, glutaminase inhibitors, etc.), etc. According to certain aspects of the present invention, one or more therapeutic agents may include anti-myeloma agents. Exemplary anti-myeloma agents include dexamethasone, melphalan, doxorubicin, bortezomib, lenalidomide, prednisone, carmustine, etoposide, cisplatin, vincristine, cyclophosphamide and thalidomide, several of which are indicated as chemotherapeutic agents, anti-inflammatory agents or immunosuppressants above.

[0159] Cancer to be treated

[0160] The methods of the present invention can improve the treatment of any cancer that can be treated using adoptive cell transfer immunotherapy targeting immunoglobulin light chains. The methods of the present invention are particularly useful in methods for treating B cell tumors. B lymphocytes express surface monoclonal immunoglobulins with kappa or lambda light chains, so it is expected that B cell tumors are generally suitable for adoptive cell transfer immunotherapy targeting immunoglobulin light chains. Examples of B cell tumors that can be treated using adoptive cell transfer immunotherapy targeting immunoglobulin light chains and that are treated in preferred embodiments of the present invention are: precursor B acute lymphoblastic leukemia / lymphoblastic lymphoma (LBL), B cell acute lymphoblastic leukemia; B cell chronic lymphocytic leukemia (CLL); small lymphocytic lymphoma; B cell prolymphocytic leukemia; lymphoplasmacytic lymphoma / immunocytoma; mantle cell lymphoma; follicular lymphoma; extranodal marginal zone B cell lymphoma of mucosa-associated lymphoid tissue (MALT) type; nodal marginal zone B cell lymphoma; splenic marginal zone lymphoma; hairy cell leukemia; plasmacytoma / plasma cell myeloma; diffuse large B cell lymphoma (such as primary mediastinal B cell lymphoma), Burkitt's lymphoma, Burkitt-like lymphoma; primary central nervous system (CNS) lymphoma and primary intraocular lymphoma. In certain embodiments, the cancer to be treated is a B-cell lymphoma. In certain embodiments, the cancer to be treated is a B-cell leukemia. In a preferred embodiment, the cancer to be treated is a B-cell non-Hodgkin lymphoma (B-NHL), particularly diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), or advanced follicular lymphoma (FL), which are determined to express a surface immunoglobulin that is clonally restricted to a kappa or lambda light chain. .

[0161] In some embodiments, the cancer to be treated is a B cell lymphoma. In some embodiments, the method of the present invention includes multiple administrations of IgG cysteine ​​proteases or IgG endoglycosidases and the cancer to be treated is a B cell lymphoma. In some such embodiments, the method for treating cancer includes administering a protein with IgG cysteine ​​protease or IgG endoglycosidase activity after administering two or more doses of adoptive cell transfer immunotherapy, wherein the adoptive cell transfer immunotherapy includes administering a CAR-T cell targeting an immunoglobulin light chain, particularly a kappa light chain or a lambda light chain. In some such embodiments, the method also includes immunosuppression. The method of the present invention can be particularly effective in treating tumors requiring immunosuppression.

[0162] In certain embodiments, the cancer to be treated expresses kappa light chains or lambda light chains on its surface. In certain embodiments, the patient to be treated has been identified as having a B-cell tumor that expresses kappa light chains or lambda light chains on its surface.

[0163] The anticancer response of patients to solid tumors is driven not only by cancer cells but also by the tumor microenvironment. This microenvironment is generated by non-malignant cells such as fibroblasts, T cells and B lymphocytes, which may be tolerant. In particular, T cells not only have tumor lytic functions, but their subsets can also develop a regulatory suppressive phenotype, thereby reducing the natural anti-tumor response of the immune system. The same dual role has been observed for B cells. For example, Breg cells (such as those producing IL10 in tumor masses) can suppress endogenous anti-tumor responses.

[0164] Removing Breg cells from the tumor environment using light chain-specific CAR T cells may be beneficial for treating cancer (Leong and Bryant, Transl Lung Cancer Res. 2021Jun; 10(6): 2830–2841). However, the use of, for example, rituximab to remove most B cells may make already weakened cancer patients more susceptible to infection. In this case, it is particularly advantageous to treat patients with CAR T cells (e.g., kappa or lambda light chain-specific CAR T cells) using the method of the present invention to remove most of the B cell blocks in the tumor while retaining the corresponding light chain B cell population to protect the patient from being completely eliminated by humoral responses. Preferably, the method of the present invention is used to treat human patients. In the case where the subject is a person, the subject can be of any age. For example, the subject can be 60 years old or older, 65 years old or older, 70 years old or older, 75 years old or older, 80 years old or older, 85 years old or older, or 90 years old or older. Alternatively, the subject can be 60 years or younger, 55 years or younger, 50 years or younger, 45 years or younger, 40 years or younger, 35 years or younger, 30 years or younger, 25 years or younger, or 20 years or younger. For human subjects with cancer, the subject can be newly diagnosed, or relapsed and / or refractory, or in remission.

[0165] Other diseases to be treated

[0166] The methods of the present invention are applicable to improve the treatment of any disease that can be treated using adoptive cell transfer immunotherapy targeting immunoglobulin light chains. A variety of autoimmune diseases are characterized by the presence of monoclonal or oligoclonal immunoglobulins carrying kappa or lambda light chains. Targeted elimination of B cells producing kappa or lambda Ig may be beneficial to these patients without completely suppressing their humoral immune system branch.

[0167] Examples of suitable diseases include Ig light chainskewed autoimmune diseases, such as juvenile arthritis (particularly juvenile idiopathic arthritis), rheumatoid arthritis, generalized lichen myxedema (scleromyxedema), Graves' disease, IgA-driven bullous dermatoses, IgG4-driven bullous pemphigoid, Sjögren's syndrome and lupus mastitis.

[0168] The methods of the present invention can be used to treat juvenile arthritis because these patients have significantly elevated levels of λ light chains (Low et al.; Scand J Immunol. 2007 Jan; 65(1): 76-83). In addition, a kappa:λ light chain skew of citrullinated protein antibodies (ACPA) has been observed in rheumatoid arthritis (Slot et al., PLoS One. 2021 Mar 30; 16(3): e0247847.).

[0169] The classic features of general scleromyxedema are a monoclonal gammopathy (usually IgGλ) and systemic symptoms, including neurologic, rheumatoid, cardiac, pulmonary, gastrointestinal, hematologic, and ocular manifestations. In addition to the predominant group of patients expressing IgGλ, there are subsets of patients expressing clonal κ or λ IgA or IgMκ.

[0170] Graves' disease is caused by activation of the thyroid stimulating hormone receptor by autoantibodies that stimulate the thyroid gland, which activates the target organ. Increased signaling leads to thyroid hyperplasia, increased thyroid hormone secretion, and clinical thyrotoxicosis, which may lead to life-threatening thyroid storm. Many patients have oligoclonal IgG1 antibodies in either kappa or lambda (Chazenbalk et al.; J Clin Invest. 2002 Jul; 110(2):209-17).

[0171] Bullous dermatoses and bullous pemphigoid are subtypes of autoimmune bullous dermatoses. Skin blisters are thought to be driven by antibodies against skin matrix components. Anti-basement membrane region antibodies are predominant in bullous pemphigoid and tend to be skewed toward the kappa light chain on IgG4. Patients who present with linear IgA bullous dermatoses may have primarily kappa or lambda light chain IgA (Flotte and Baird; J Immunol. 1986 Jan; 136 (2): 491-6.).

[0172] IgAλ preference has also been observed in Sjögren's syndrome (Jasani; J Pathol. 1988 Jan; 154(1): 1-5.).

[0173] In some cases of lupus mastitis, it was observed that the infiltrating plasma cells of the patient were restricted by kappa light chains but did not show the immunophenotype of plasma cell tumors (Yan et al. Surgical and Experimental Pathology volume 3, Article number: 24 (2020)). Such patients may benefit from treatment using the methods of the present invention.

[0174] IgG Cysteine ​​Protease

[0175] The inventors have demonstrated that the use of IgG cysteine ​​proteases protects cells and improves their survival and can therefore be used in combination with adoptive cell transfer immunotherapy to treat cancer.The IgG cysteine ​​proteases used in the present invention are specific for IgG, the major antibody class in mammalian plasma.

[0176] In a preferred embodiment, the protease used in the method of the present invention is imlifidase (IdeS) (immunoglobulin G degrading enzyme of Streptococcus pyogenes (S. pyogenes)). IdeS is an extracellular cysteine ​​protease produced by the human pathogen Streptococcus pyogenes. IdeS was originally isolated from a group A streptococcal strain of serotype M1, but the ides gene has now been identified in all tested group A streptococcal strains. IdeS has extremely high substrate specificity, and its only recognizable substrate is IgG. IdeS catalyzes a single proteolytic cleavage of the lower hinge region of the heavy chain of all subclasses of human IgG. IdeS also catalyzes equivalent cleavage of the heavy chains of some IgG subclasses in various animals. IdeS effectively cleaves IgG into Fc and F(ab')2 fragments through a two-stage mechanism. In the first stage, one (first) heavy chain of IgG is cleaved to produce a single cleaved IgG (scIgG) molecule with a non-covalently bound Fc molecule. The scIgG molecule is actually an intermediate product that retains the remaining (second) heavy chain of the original IgG molecule. In the second stage of the mechanism, the second heavy chain is cleaved by IdeS to release the F(ab')2 fragment and the homodimeric Fc fragment. These are the products normally observed under physiological conditions. Under reducing conditions, the F(ab')2 fragment can be dissociated into two Fab fragments, and the homodimeric Fc can be dissociated into its constituent monomers. SEQ ID NO: 1 is the complete sequence of IdeS, including the N-terminal methionine and signal sequence. It can also be obtained by NCBI reference sequence number WP_010922160.1. SEQ ID NO: 2 is the mature sequence of IdeS, lacking the N-terminal methionine and signal sequence. It can also be obtained by Genbank accession number ADF13949.1.

[0177] In an alternative embodiment, the protease used in the method of the present invention is IdeZ, which is an IgG cysteine ​​protease produced by Streptococcus equi ssp. Zooepidemicus, a bacterium found primarily in horses. SEQ ID NO: 3 is the complete sequence of IdeZ, including the N-terminal methionine and signal sequence. It can also be obtained from NCBI reference sequence number WP_014622780.1. SEQ ID NO: 4 is the mature sequence of IdeZ, lacking the N-terminal methionine and signal sequence.

[0178] In an alternative embodiment, the protease used in the methods of the invention is a hybrid IdeS / Z, such as the protease of SEQ ID NO: 5. The N-terminus is based on IdeZ lacking the N-terminal methionine and the signal sequence.

[0179] In a preferred embodiment, the protease used in the present invention may comprise SEQ ID NO: 2, 4 or 5 and consist of SEQ ID NO: 2, 4 or 5. The protease used in the present invention may comprise an additional methionine (M) residue at the N-terminus and / or a tag at the C-terminus to facilitate expression in and isolation from standard bacterial expression systems. Suitable tags include histidine tags, which may be linked directly to the C-terminus of the polypeptide or indirectly via any suitable linker sequence (e.g., 3, 4 or 5 glycine residues). The histidine tag typically consists of six histidine residues, although it may be longer than this, typically up to 7, 8, 9, 10 or 20 amino acids, or shorter, such as 5, 4, 3, 2 or 1 amino acids.

[0180] In a further preferred embodiment, the protease used in the present invention may comprise, consist essentially of or consist of the sequence of any one of SEQ ID NOs: 6-25. These sequences represent IdeS and IdeZ polypeptides with increased protease activity and / or reduced immunogenicity. Each of SEQ ID NOs: 6-25 may optionally comprise an additional methionine at the N-terminus and / or a histidine tag at the C-terminus. The histidine tag preferably consists of six histidine residues. The histidine tag is preferably connected to the C-terminus via a linker of 3x glycine or 5x glycine residues.

[0181] In a further preferred embodiment, the protease used in the present invention may comprise, consist essentially of, or consist of the sequence of any one of SEQ ID NOs: 56-69. These sequences represent IdeS polypeptides with increased protease activity and / or reduced immunogenicity. Each of SEQ ID NOs: 56-69 may optionally comprise an additional methionine at the N-terminus and / or a histidine tag at the C-terminus. The histidine tag preferably consists of six histidine residues. The histidine tag is preferably connected to the C-terminus via a linker of 3x glycine or 5x glycine residues.

[0182] In a further preferred embodiment, the protease used in the present invention may comprise, consist essentially of or consist of the sequence of any one of SEQ ID NOs: 6-25, optionally with up to 3 (e.g. 1, 2 or 3) amino acid substitutions. Each of SEQ ID NOs: 6-25 and variants thereof may optionally comprise an additional methionine at the N-terminus and / or a histidine tag at the C-terminus.

[0183] In a further preferred embodiment, the protease used in the present invention may comprise, consist essentially of or consist of the sequence of any one of SEQ ID NOs: 56-69, optionally with up to 3 (e.g. 1, 2 or 3) amino acid substitutions. Each of SEQ ID NOs: 56-69 and variants thereof may optionally comprise an additional methionine at the N-terminus and / or a histidine tag at the C-terminus.

[0184] In a further preferred embodiment, the protease for use in the present invention may comprise, consist essentially of, or consist of the sequence of SEQ ID NO:91, SEQ ID NO:92, or a variant of SEQ ID NO:91 or SEQ ID NO:92 having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications relative to SEQ ID NO:91 or SEQ ID NO:92, respectively, with the proviso that the sequence retains: (a) asparagine (N) at position corresponding to position 95 of SEQ ID NO:3, (b) aspartic acid (D) at position corresponding to position 99 of SEQ ID NO:3, and (c) asparagine (N) at position corresponding to position 226 of SEQ ID NO:3, and with the proviso that the polypeptide is at least as effective at cleaving human IgG as a polypeptide consisting of the amino acid sequence of SEQ ID NO:91 or 92, respectively, when measured in the same assay. Preferably, at least one modification or all modifications do not result in an amino acid identical to the amino acid present at the corresponding position in the polypeptide sequence of SEQ ID NO:4.

[0185] The length of polypeptide of the present invention is generally at least 100,150,200,250,260,270,280,290,300 or 310 amino acids. The length of polypeptide of the present invention is generally no more than 400,350,340,330,320 or 315 amino acids. It should be understood that any one of the lower limits listed above can be combined with any one of the upper limits listed above to provide the length range of polypeptide of the present invention. For example, the length of polypeptide can be 100 to 400 amino acids, or 250 to 350 amino acids. The length of polypeptide is preferably 290 to 320 amino acids, most preferably 300 to 315 amino acids.

[0186] The primary structure (amino acid sequence) of the protease of the present invention is based on the primary structure of IdeS, IdeZ or IdeS / Z, specifically based on the amino acid sequence of SEQ ID NO: 2, 4 or 5, respectively. The sequence of the protease of the present invention may comprise a variant of the amino acid sequence of SEQ ID NO: 2, 4 or 5, which variant is at least 80% identical to the amino acid sequence of SEQ ID NO: 2, 4 or 5. The variant sequence may be at least 80%, at least 85%, preferably at least 90%, at least 95%, at least 98% or at least 99% identical to the sequence of SEQ ID NO: 2, 4 or 5. The variant may be identical to the sequence of SEQ ID NO: 2, 4 or 5, except for containing one or more specific modifications specified in WO2016 / 128558 or WO2016 / 128559. The identity relative to the sequence of SEQ ID NO: 2, 4 or 5 can be measured over a region of at least 50, at least 100, at least 200, at least 300 or more contiguous amino acids of the sequence shown in SEQ ID NO: 2, 4 or 5, or more preferably over the entire length of SEQ ID NO: 4 or 5.

[0187] The protease used in the present invention can be an IdeS, IdeZ or IdeS / Z polypeptide comprising a variant of the amino acid sequence of SEQ ID NO: 2, 4 or 5, wherein the modification (e.g., amino acid addition, deletion or substitution) is made relative to the sequence of SEQ ID NO: 2, 4 or 5. Such modifications are preferably conservative amino acid substitutions. Conservative substitutions replace amino acids with other amino acids of similar chemical structure, similar chemical properties or similar side chain volume. The introduced amino acids can have similar polarity, hydrophilicity, hydrophobicity, basicity, acidity, neutrality or charge as the amino acids they replace. Alternatively, conservative substitutions can introduce another aromatic or aliphatic amino acid to replace a previously existing aromatic or aliphatic amino acid. Conservative amino acid changes are well known in the art.

[0188] IgG cysteine ​​protease activity can be assessed by any suitable method, such as by incubating the polypeptide with a sample containing IgG and determining the presence of IgG cleavage products. Suitable methods are described in WO2016 / 128559. Suitable assays include ELISA-based assays, such as those described in WO2016 / 128559. In such assays, the wells of the assay plate are usually coated with an antibody target, such as bovine serum albumin (BSA). The polypeptide sample to be tested is then added to the well, followed by a sample of a target-specific antibody, which is a BSA-specific antibody in this embodiment. The polypeptide and antibody are allowed to interact under conditions suitable for IgG cysteine ​​protease activity. After a suitable time interval, the assay plate is washed, and a detection antibody specifically bound to the target-specific antibody is added under conditions suitable for binding to the target-specific antibody. The detection antibody will bind to any complete target-specific antibody in each well that has been bound to the target. After washing, the amount of the detection antibody present in the well will be proportional to the amount of the target-specific antibody bound to the well. The detection antibody may be conjugated directly or indirectly to a label or another reporter system (e.g., an enzyme) so that the amount of detection antibody remaining in each well can be determined. The higher the potency of the test polypeptide in the well, the less intact target-specific antibody remains, and therefore the less detection antibody. Typically, at least one well on a given assay plate will contain IdeS instead of the polypeptide to be tested so that the potency of the test polypeptide can be compared directly to that of IdeS. IdeZ and IdeS / Z may also be included for comparison.

[0189] Other assays can determine the effectiveness of the test polypeptide by directly observing and / or quantifying the IgG fragments produced by the test polypeptide cleaving IgG. This type of assay is also described in WO2016 / 128559. This assay typically incubates the IgG sample with different concentrations of the test polypeptide (or with one or more of IdeS, IdeZ and IdeS / Z as a control) under a titration series. The products produced by incubation at each concentration are then separated using gel electrophoresis (e.g., by SDS-PAGE). The intact IgG and the fragments produced by IgG cleavage can then be identified by size and quantified by the intensity of staining with a suitable dye. The more the number of cleavage fragments, the greater the effectiveness of the test polypeptide at a given concentration. The polypeptides of the present invention will typically produce detectable amounts of cleavage fragments at concentrations lower than IdeZ and / or IdeS (lower points in the titration series). This type of assay can also identify test polypeptides that are more effective in cleaving the first heavy chain or second heavy chain of IgG molecules, because the amount of different fragments produced by each cleavage event can also be determined. The polypeptides of the invention are more efficient at cleaving the first chain of an IgG molecule than the second chain, particularly when the IgG is of the IgG2 isotype. The polypeptides of the invention may be more efficient at cleaving IgG1 than IgG2.

[0190] IgG endoglycosidase

[0191] The inventors have demonstrated that the use of IgG endoglycosidases protects cells and improves their survival and can therefore be used in conjunction with adoptive cell transfer immunotherapy to treat cancer. The IgG endoglycosidases used in the present invention are specific for IgG, the major antibody class in mammalian plasma.

[0192] The agent may be a protein having IgG endoglycosidase activity, preferably cleaving the glycan moiety at Asn-297 (Kabat numbering) of the Fc region of IgG. A preferred example of such a protein is EndoS (endoglycosidase of Streptococcus pyogenes), which has been shown to be effective in the Examples. EndoS hydrolyzes the β-1,4-di-N-acetylchitobiose core of the asparagine-linked glycans of normally glycosylated IgG (see Figure 18). The mature sequence of EndoS is provided as SEQ ID NO: 90. The protein may comprise or consist of the amino acid sequence of SEQ ID NO: 90, or may be a homolog thereof from an alternative bacterium, such as Streptococcus equi or Streptococcus zooepidemicus, or Corynebacterium pseudotuberculosis, Enterococcus faecalis or Elizabethella meningoseptica. The agent may be CP40, EndoE or EndoF2.

[0193] Alternatively, the protein may be a variant of the EndoS protein comprising or consisting of any amino acid sequence that is at least 80%, 85%, 90% or 95% identical to SEQ ID NO: 90 and has IgG endoglycosidase activity. The variant of the EndoS protein may comprise or consist of an amino acid sequence having up to 1, 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90 or more amino acid substitutions, insertions or deletions relative to the amino acid sequence of SEQ ID NO: 90, provided that the variant has IgG endoglycosidase activity. The amino acid substitutions are preferably conservative.

[0194] Alternatively, the agent may be a protein comprising or consisting of a fragment of SEQ ID NO: 90 and having IgG endoglycosidase activity, preferably wherein the fragment is 400 to 950, 500 to 950, 600 to 950, 700 to 950, or 800 to 950 amino acids in length. A preferred fragment consists of amino acids 1-409 of SEQ ID NO: 90, which corresponds to the enzymatically active α-domain of EndoS produced by cleavage by the Streptococcal cysteine ​​protease SpeB. The fragment may be generated by deleting one or more amino acid residues of the amino acid sequence of SEQ ID NO: 90. Up to 1, 2, 3, 4, 5, 10, 20, 30, 40, 50, 100, 200, 300, 400, 500 or 550 residues, or more, may be deleted. Deleted residues may be adjacent to other deleted residues.

[0195] Any fragment or variant of SEQ ID NO: 2 preferably includes residues 191-199 of SEQ ID NO: 90, i.e., Leu-191, Asp-192, Gly-193, Leu-194, Asp-195, Val-196, Asp-197, Val-198, and Glu-199 of SEQ ID NO: 1. These amino acids form a perfect chitinase family 18 active site, ending with glutamic acid. Glutamic acid in the chitinase active site is essential for enzyme activity. Therefore, most preferably, the variant of SEQ ID NO: 90 includes Glu-199 of SEQ ID NO: 90. The variant of SEQ ID NO: 2 may include residues 191-199 of SEQ ID NO: 90 with one or more conservative substitutions, provided that the variant includes Glu-199 of SEQ ID NO: 90.

[0196] Assessment of IgG levels and administration timing

[0197] The appropriate time for administering proteins with IgG cysteine ​​protease or IgG endoglycosidase activity and adoptive cell transfer immunotherapy in the methods of the invention can be determined using, for example, an assay for assessing plasma or serum IgG levels. For example, the amount of time it takes for a protein to inactivate or eliminate the binding of Fc receptors and / or complement to substantially all IgG molecules present in the serum or plasma of a subject can be measured. This can be determined alternatively by testing serum or plasma samples taken from an individual and applying any suitable assay. Some exemplary suitable assays are described in the Examples.

[0198] Such an assay can directly test the presence of IgG molecules capable of binding to one or more Fc receptors in a serum or plasma sample, for example, in an ELISA. Alternatively, such an assay can be indirect, in that it can test for the presence of one or more reaction products expected to be produced by treating IgG with a protein having IgG cysteine ​​protease or IgG endoglycosidase activity. For example, when the reagent is an enzyme that cleaves IgG protein, the presence of intact IgG molecules or fragments produced by cleavage can be analyzed in the serum or plasma sample. This can be achieved by any suitable method, such as by separating molecules and fragments based on molecular weight (e.g., by mass spectrometry or SDS-PAGE), or by specific detection of molecules or fragments (e.g., by ELISA). Alternatively, IgG can be detected by mixing the serum or plasma of the subject with cells expressing FcgR and monitoring IgG binding by flow cytometry using anti-human IgG conjugated to a fluorescent dye.

[0199] Conventional methods for assessing the amount of IgG in samples (e.g., serum or plasma samples) in a clinical setting rely on nephelometry and turbidimetry because of their speed, ease of use, and accuracy. In nephelometry and turbidimetry, a light source is projected through a liquid sample in a transparent container. Nephelometry measures the decrease in light intensity, and turbidimetry measures the scattering of light as it passes through a sample, which is proportional to the concentration of immunoglobulins in the solution. Both principles are based on the reaction of added anti-IgG antibodies with antigens in the sample to form antigen / antibody complexes (agglutination). The addition of PEG allows the reaction to proceed quickly to the endpoint, improves sensitivity, and reduces the risk of false negative results for samples containing excess antigen. In the case of IgG analysis, the F(ab')2 portion of IgG is cross-linked with anti-IgG antibodies and causes an agglutination reaction. However, such methods may not be suitable when some or all of the IgG present may be incomplete. For example, if an IgG cysteine ​​protease (such as IdeS) has been administered to the subject from which the sample was collected (e.g., in the methods of the present invention), or if such a protease has been administered to the sample, cleavage fragments such as F(ab')2 fragments and Fc fragments will be present. This will not affect the agglutination reaction of conventional nephelometry and turbidimetry as long as the F(ab')2 fragments are still present in the sample. Since the half-life of the F(ab')2 fragment is shorter than that of intact IgG, agglutination will decrease over time, although it is not proportional to the amount of intact IgG present in the sample. Therefore, samples affected by the presence of IgG cysteine ​​proteases (such as IdeS) cannot be evaluated by conventional methods. The inventors have developed a new IgG concentration assay that is compatible with samples affected by the presence of IgG cysteine ​​proteases (such as IdeS) and can be used in any clinical setting, including (but not limited to) in combination with other methods of the present invention.

[0200] The method is able to distinguish between intact IgG and F(ab')2 fragments generated by IdeS. This is achieved by using antibodies that detect different fragments (i.e., anti-Fab antibodies and anti-Fc antibodies). The antibodies used in the assay must not be substrates for IgG cysteine ​​proteases (usually IdeS) that affect the sample. This avoids the assay reagents being affected by any active proteases that may be present in the sample. This can be achieved by testing IgG from different species or by using antibody fragments (i.e., Fab fragments or F(ab')2 fragments) instead of whole antibodies. Typically, anti-F(ab')2 reagents are incubated with the sample as capture reagents. The capture reagents are typically fixed in wells of, for example, an assay plate. The bound IgG is then detected by incubating with an anti-Fc reagent as a detection reagent. Therefore, in contrast to nephelometry and turbidimetry, only IgGs with both Fab and Fc parts will be detected. The detection reagent can typically be conjugated directly or indirectly to a moiety that facilitates detection, such as a fluorescent dye or an enzyme that reacts with a chromogenic substrate. The capture reagent and detection reagent can be any other molecule that specifically recognizes the Fab portion or the Fc portion of IgG, and can be used in the reverse order, i.e., capture with anti-Fc and detection with anti-Fab. The assay can be performed in any suitable format, such as a conventional ELISA or Meso Scale Discovery format.

[0201] In some cases, such as when the IgG cysteine ​​protease is IdeS, the sample may contain intermediate fragments, such as scIgG, in which only one heavy chain is cut and F(ab')2 is still connected to another complete heavy chain. In this case, the scIgG fragment may be mistakenly identified as a complete IgG by the assay. Therefore, the method may include a supplementary step of evaluating the size of the fragments present in the sample. Since there are no disulfide bridges between the heavy chains below the hinge region, the Fc portion of the heavy chain in the scIgG fragment will be separated from the complete heavy chain under denaturing conditions to become a protein of approximately 20-25 kDa. Any suitable method (such as SDS-PAGE) can be used to detect and quantify different fragment sizes. Specific embodiments of the method (including optional supplementary steps) are described in Example 1 (see Efficacy Evaluation). The method is particularly useful for evaluating the efficacy of IdeS in a clinical setting.

[0202] When the protein having IgG cysteine ​​protease or IgG endoglycosidase activity is the enzyme that cleaves the glycan moiety on IgG, the presence of IgG molecules with normal or truncated glycans, or glycan fragments resulting from cleavage, can be determined in a serum or plasma sample. This can be achieved by any suitable method, such as by separating molecules and / or fragments based on molecular weight (e.g., by mass spectrometry or SDS-PAGE), or by specific detection of molecules or fragments (e.g., by ELISA).

[0203] In the method of administering a protein having IgG cysteine ​​protease or IgG endoglycosidase activity prior to adoptive cell transfer immunotherapy, the lower limit of the time interval between administration of the protein having IgG cysteine ​​protease or IgG endoglycosidase activity and the adoptive cell transfer immunotherapy can be selected from: at least 30 minutes, at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours or at least 6 hours. If it is determined that the binding of substantially all IgG molecules present in the subject's serum or plasma to Fc receptors has been sufficiently reduced or eliminated at an earlier time point, the lower limit can be shorter than any of the above lower limits. Preferably, the lower limit is 2 hours.

[0204] In the method of administering a protein having IgG cysteine ​​protease or IgG endoglycosidase activity prior to adoptive cell transfer immunotherapy, the upper limit of the time interval between administering a protein having IgG cysteine ​​protease or IgG endoglycosidase activity and adoptive cell transfer immunotherapy can be selected independently of the lower limit and can be determined by the time it takes for endogenous production of IgG to begin to replace or completely replace the IgG molecules present in the serum or plasma of the subject before the method is performed. This can be determined by testing a serum or plasma sample taken from an individual and applying any suitable assay, such as those described above for the lower limit. Newly synthesized IgG will typically begin to reappear in plasma within 3-4 days and complete complete replacement at approximately 3 weeks (21 days). Therefore, the upper limit can be selected from: at most 21 days, at most 18 days, at most 14 days, at most 13 days, at most 12 days, at most 11 days, at most 10 days, at most 9 days, at most 8 days, at most 7 days, at most 6 days, at most 5 days, at most 4 days, at most 3 days, at most 2 days, at most 24 hours, at most 18 hours, at most 12 hours, at most 10 hours, at most 8 hours, at most 7 hours, at most 6 hours, at most 5 hours, at most 4 hours, at most 3 hours, at most 2 hours or at most 1 hour. Preferably, the upper limit is 48 hours.

[0205] The time interval between the administration of the protein having IgG cysteine ​​protease or IgG endoglycosidase activity and the adoptive cell transfer immunotherapy may be up to 24 hours, up to 12 hours or up to 6 hours, so that the administration steps (a) and (b) can be performed on the same day or during the same treatment center visit. This is very advantageous, especially in cases where access to treatment centers may be limited.

[0206] In a method for increasing the efficacy of immunotherapy by administering a protein having IgG cysteine ​​protease or IgG endoglycosidase activity after adoptive cell transfer immunotherapy, the time of administration depends on the increase in IgG ADA. In certain embodiments, the protein is administered 4-8 days, for example 5-7 or 6 days after adoptive cell transfer immunotherapy. If the antibody response is a recall response, this time may be appropriate. If the antibody response is a primary response, the protein may be administered more than one week after adoptive cell transfer immunotherapy, for example 10 days, 2 weeks, 3 weeks or 4 weeks, or between 10 days and 2 weeks, between 10 days and 3 weeks, between 2 weeks and 4 weeks.

[0207] Safety switch

[0208] When administering any type of adoptive cell transfer immunotherapy, a worrying problem is that severe cytokine release syndrome (CSR) or other complications may occur. Therefore, for safety reasons, it is best to temporarily stop the lysis of target cells by adoptive cell transfer immunotherapy. Suitable means for achieving it are known in the art. For example, the exhaustion of CAR T cells can be achieved by designing a CAR construct that also expresses a suicide gene, such as inducible Caspase 9 (iCasp9), herpes simplex virus tyrosine kinase (HSV-TK) or human thymidylate kinase (TMPK).

[0209] For B cell receptor (BCR)-specific CAR T cells, BCR is the triggering target of kappa or light chain CAR T cells. Temporarily removing BCR from the cell surface will reduce the activity of effector CAR T cells.

[0210] Removal of CAR can be achieved in a variety of ways. For example, cells can be engineered to contain CAR spacers that connect the extracellular ligand binding domain and the intracellular signaling domain. Advantageously, these spacers can be easily cleaved by proteases. This is useful because CAR T cells with any given scFv specificity containing these spacers may be temporarily blinded when exposed to proteases, potentially eliminating all CAR T cells in the patient.

[0211] Preferably, the spacer may comprise a constant region of an IgG (e.g., IgG1 or IgG4). In these embodiments, the spacer may be cleaved by an IgG cleavage enzyme such as imlifidase. These CAR spacers may comprise a CH2 or CH2-CH3 domain. The IgG may have a wild-type sequence, or may mutate. For example, the spacer may mutate to reduce FcR-mediated cell recognition in vivo compared to a CAR T cell that does not comprise a spacer having a mutation.

[0212] Suitable spacers are known in the art. For example, Jonnalagadda et al. (Mol Ther. 2015Apr; 23(4): 757–768) described a CAR T containing an IgG4 Fc spacer that contained mutations that reduced FcR binding. Similarly, Savoldo et al. (J Clin Invest. 2011May; 121(5): 1822-6) described a CAR T that contained a spacer derived from a human IgG1-CH2CH3 domain that was cloned in-frame between the scFv and the signaling domain (see also Hudecek et al. (Cancer Immunol Res. 2015Feb; 3(2): 125-35)).

[0213] These can also be performed using other IgG cleaving enzymes, for example cysteine ​​proteases such as the one cloned from Bdellovibrio bacteriovorus, or gingipains.

[0214] Alternatively, the IgG cysteine ​​protease is administered prior to the administration of the adoptive cell transfer immunotherapy. In these embodiments, it is preferred to allow sufficient time (preferably more than 3 days, such as more than 4 days, more than 5 days, more than 6 days, more than 7 days, more than 8 days, more than 9 days or more than 10 days) between the administration of the IgG cysteine ​​protease and the start of the adoptive cell transfer immunotherapy to allow at least some or all of the protease to be cleared from the patient's blood. The skilled person will know the appropriate time range.

[0215] Peptide production

[0216] As disclosed herein, polypeptides can be produced by any suitable means. For example, polypeptides can be directly synthesized using standard techniques known in the art, such as Fmoc solid phase chemistry, Boc solid phase chemistry, or by liquid phase peptide synthesis. Alternatively, polypeptides can be produced by transforming cells (usually bacterial cells) with nucleic acid molecules or vectors encoding the polypeptides. The production of polypeptides by expression in bacterial host cells is described and illustrated in WO2016 / 128559.

[0217] Compositions and preparations containing polypeptides

[0218] The present invention also provides compositions comprising IgG cysteine ​​proteases or IgG endoglycosidases for use in the methods of treatment of the present invention. For example, the present invention provides compositions comprising one or more polypeptides of the present invention and at least one pharmaceutically acceptable carrier or diluent. The carrier needs to be "acceptable" in the sense that it is compatible with the other ingredients of the composition and is harmless to the object to which the composition is administered. Typically, the carrier and the final composition are sterile and pyrogen-free.

[0219] The preparation of suitable compositions can be carried out using standard pharmaceutical formulation chemistry and methods, all of which are readily available to fairly skilled technicians. For example, the reagent can be combined with one or more pharmaceutically acceptable excipients or solvents. Auxiliary substances (such as wetting agents or emulsifiers, pH buffer substances, reducing agents, etc.) can be present in the excipient or solvent. Suitable reducing agents include cysteine, thioglycerol, thioreducin, glutathione, etc. Excipients, solvents and auxiliary substances are generally pharmaceutical preparations that do not induce an immune response in the individual receiving the composition and can be administered without abnormal toxicity. Pharmaceutically acceptable excipients include, but are not limited to: liquids, such as water, saline, polyethylene glycol, hyaluronic acid, glycerol, thioglycerol and ethanol. Pharmaceutically acceptable salts may also be included, such as inorganic acid salts, such as hydrochlorides, hydrobromides, phosphates, sulfates, etc.; and salts of organic acids, such as acetates, propionates, malonates, benzoates, etc. A thorough discussion of pharmaceutically acceptable excipients, vehicles, and auxiliary substances may be found in Remington's Pharmaceutical Sciences (Mack Pub. Co., NJ 1991).

[0220] Such compositions can be prepared, packaged or sold in a form suitable for single administration (bolus administration) or continuous administration. Injectable compositions can be prepared, packaged or sold in unit dosage form (e.g., in ampoules or multidose containers containing preservatives). Compositions include, but are not limited to, suspensions, solutions, emulsions in oily or aqueous vehicles, pastes, and implantable sustained-release or biodegradable formulations. Such compositions may also include one or more additional ingredients, including, but not limited to, suspending agents, stabilizers or dispersants. In one embodiment of a composition for parenteral administration, the active ingredient is provided in a dry (e.g., powder or granular) form for reconstitution with a suitable solvent (e.g., sterile pyrogen-free water) and then parenterally administering the reconstructed composition. Compositions may be prepared, packaged or sold in the form of sterile injectable aqueous or oily suspensions or solutions. The suspension or solution may be prepared according to known techniques and, in addition to the active ingredient, may also include other ingredients, such as dispersants, wetting agents or suspending agents described herein. Such sterile injectable preparations can be prepared using a parenterally acceptable non-toxic diluent or solvent such as water or 1,3-butanediol. Other acceptable diluents and solvents include, but are not limited to, Ringer's solution, isotonic sodium chloride solution, and non-oily oils such as synthetic mono- or di-glycerides.

[0221] Other useful parenteral compositions include those compositions comprising active ingredients in microcrystalline form, in liposome formulations or as components of biodegradable polymer systems. Compositions for sustained release or implantation may include pharmaceutically acceptable polymers or hydrophobic materials, such as emulsions, ion exchange resins, slightly soluble polymers or slightly soluble salts. Compositions may be suitable for use by any suitable route, including, for example, intradermal, subcutaneous, percutaneous, intramuscular, intraarterial, intraperitoneal, intraarticular, intraosseous or other suitable routes of administration. Preferred compositions are suitable for use by intravenous infusion.

[0222] General

[0223] It should be understood that different applications of the disclosed products and methods can be customized to specific needs in the art.It should also be understood that the terminology used herein is for the purpose of describing particular embodiments of the present invention only and is not intended to be limiting.

[0224] In addition, as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to "a polypeptide" includes "polypeptides" and the like.

[0225] Unless specifically prohibited, the steps of the methods disclosed herein may be performed in any suitable order and the order in which the steps are listed should not be construed as limiting.

[0226] "Polypeptide" is used in its broadest sense herein to refer to a compound having two or more subunit amino acids, amino acid analogs or other peptidomimetics. Thus, the term "polypeptide" includes short peptide sequences as well as longer polypeptides and proteins. As used herein, the term "amino acid" refers to natural amino acids and / or unnatural amino acids or synthetic amino acids, including D or L optical isomers, as well as amino acid analogs and peptidomimetics.

[0227] The terms "patient" and "subject" are used interchangeably and typically refer to a human. References to IgG typically refer to human IgG unless otherwise specified.

[0228] Amino acid identity as described above can be calculated using any suitable algorithm. For example, PILEUP and BLAST algorithms can be used to calculate identity or arrange sequences (e.g., identify equivalent sequences or corresponding sequences (usually with their default settings)), such as Altschul SF (1993) J Mol Evol 36:290-300; Altschul, S, F et al (1990) J Mol Biol 215:403-10. Software for performing BLAST analysis can be publicly available through the National Center for Biotechnology Information (National Center for Biotechnology (http: / / www.ncbi.nlm.nih.gov / )). This algorithm involves first identifying high scoring sequence pairs (Highscoring sequence pair, HSP) by identifying a short word (word) of length W in the query sequence, which matches or satisfies some positive threshold score T when aligned with a field of the same length in the database sequence. T is referred to as the neighborhood field score threshold (as described above, Altschul et al, supra). This initial neighborhood word hit acts as a seed to initiate a search to find HSPs containing them. Word hits are extended in both directions along each sequence as long as the cumulative alignment score can be increased. Extension of word hits in each direction is stopped when: the cumulative alignment score is zero or below zero due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLAST program uses a word length (W) of 11, a BLOSUM62 scoring matrix (see Henikoff and Henikoff (1992) Proc. Natl. Acad. Sci. USA 89: 10915-10919) alignment (B) 50, an expectation (E) of 10, M = 5, N = 4, and a comparison of both chains by default.

[0229] The BLAST algorithm performs a statistical analysis of the similarity between two sequences; see, e.g., Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90: 5873-5787. A measure of similarity provided by the BLAST algorithm is the minimum sum probability (P(N)), which provides an indication of the probability that a match between two polynucleotide or amino acid sequences occurs by chance. For example, a sequence is considered to be similar to another sequence if, in a comparison of a first sequence to a second sequence, the minimum sum probability is less than about 1, preferably less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001. Alternatively, the UWGCG package provides the BESTFIT program, which can be used to calculate identity (e.g., when used under its default settings) (Devereux et al (1984) Nucleic Acids Research 12, 387-395).

[0230] All publications, patents and patent applications cited in this application, whether supra or infra, are hereby incorporated by reference in their entirety.

[0231] Example

[0232] The experiments in Examples 1 to 5 were performed to investigate whether pre-existing or treatment-induced antibodies have a negative effect on CAR T cells and whether these effects can be mitigated by treatment with imlifidase or EndoS. Systems that mimic the binding of anti-drug antibodies to CAR T cells were developed by employing in vitro and in vivo models of IgG binding to cell surface receptors. These models mimic the antibody-mediated effector mechanism of surface-bound antibodies on chimeric antigen receptors. The effects of treatment with imlifidase or EndoS in the model system were investigated.

[0233] Unless otherwise indicated, the methods used are standard biochemistry and molecular biology techniques. Examples of suitable methodological textbooks include Sambrook et al., Molecular Cloning, A Laboratory Manual (1989) and Ausubel et al., Current Protocols in Molecular Biology (1995), John Wiley and Sons, Inc.

[0234] Materials and Methods - Examples 1-4

[0235] Animals and cell lines

[0236] Balb / c JBomTac, 6-week-old females were purchased from Taconic and acclimatized before use at 9 weeks of age. Mice were housed and handled according to ethical approval M72-13 (Lund).

[0237] Daudi cells (ACC78) and THP1 monocytic cell line (AML; TIB-202) were cultured in complete D-MEM 10 medium (glutamine D-MEM, 5% FCS and PEST).

[0238] Antibodies and complement

[0239] Rabbit anti-mouse platelet IgG (serum) (code # CLA31440, lot number 6327, Cederland) was purified with protein G. The purified IgG was treated with IdeS to produce scIgG and fully cleaved Fc / F(ab')2 fractions for immune thrombocytopenia (ITP) experiments. The purity of the cleavage products was confirmed by SDS-page gel analysis.

[0240] Anti-CD20 IgG (rituximab, N7022, 10 mg / mL) was purchased from Mabthera, and human IgG1 isotype negative control (#I5154) was purchased from Sigma.

[0241] CCK-8 is a cell counting kit from Dojindo Laboratories, Japan, and was used according to the instructions.

[0242] Baby rabbit serum complement (CL3441; Lot No. 6374; Cedarlane) was reconstituted with sterile water before use and diluted in culture medium at a final dilution of 1:10.

[0243] Human blood was collected in BD CAT tubes (#368815; spray dried coagulant (silica, PVP, L-720)) for serum and frozen at -20° C. Serum was tested for low toxicity to Daudi cells before use as a complement source.

[0244] Mouse anti-human C4d (A213, Quidel) was biotinylated in-house and used for cell staining at 1 μg / ml.

[0245] Polyclonal sheep anti-human C1q (MD-14-0162, Raybiotech) was fragmented into F(ab')2 and purified using the FragIT kit (A2-FR2-025, Genovis) (final staining concentration 75 μg / ml). Donkey anti-sheep IgG (H+L)-bio (Jackson, 713-065-003) was used as detection antibody (2.5 μg / ml) together with the fluorescent dye SA-PE (BD-Pharmingen, #554061).

[0246] 7-AAD (Sigma, A9400) was used as a dead cell marker in the CDC assay.

[0247] For ADCP assay, THP1 cells were stained with FarRed DDAO-SE (Molecular Probes, C34553, batch number: 33C1-1) in DMSO (about 2 mM) (1 mg / ml), and Daudi cells were stained with Calcein AM (Invitrogen, C3099, batch number 25257W) (1 mg / ml stock solution in DMSO).

[0248] Enzymes

[0249] His-tagged-EndoS from Streptococcus pyogenes was expressed in E. coli and purified. Lipopolysaccharide (LPS) was removed using Endo Trap blue matrix. Purity was controlled on SDS-page gel. Additional protein bands beyond the expected 100 kD band after His-tag purification were shown by mass spectrometry to be not host cell proteins but EndoS derived proteins.

[0250] IdeS (IgG-degrading enzyme from Streptococcus pyogenes) is a secreted cysteine ​​endopeptidase from the human pathogen Streptococcus pyogenes that catalyzes a single proteolytic cleavage at the lower hinge of human immunoglobulin G (IgG) antibodies with high specificity.

[0251] Example 1 - Antibody-mediated complement binding on target cells

[0252] The effects of pre-existing or treatment-induced antibodies on cell therapy and the effects of IdeS and EndoS on such antibodies were investigated using rituximab (RTX)-opsonized CD20-positive Daudi cells, a model system for ADA interactions in CAR-T therapy, in the sense that receptor-specific antibodies (RTX) bind to cell surface receptors (CD20) similar to the binding of ADA to CAR.

[0253] Complement deposition on Daudi cells

[0254] Daudi cells (50 μl, 3x10E7 / ml) were treated with anti-CD20 antibody RTX or human IgG1 negative control antibody at a final concentration of 2 μg / ml and a 1:10 gradient titration of IdeS or EndoS, starting at 100 μg / ml and decreasing to a final concentration of 0.01 μg / ml enzyme. A 96V well master plate with a total volume of 150 μl / well was incubated at 37°C for 110 minutes. The plate was centrifuged and a 50 ul volume of supernatant was removed. Complement in the form of 100 μl of human serum was added at a 1:5 dilution, resulting in a final serum dilution of 1:10. The plate was incubated at 37°C for 120 minutes. All dilutions and washing steps were performed in D-MEM supplemented with 0.5% BSA.

[0255] Flow cytometric staining of complement deposition on cells

[0256] C1q complement binding was assessed by incubation with sheep anti-C1q F(ab')2 generated from a polyclonal IgG (#MD-14-0162; RayBiotech) that had been previously cleaved into Fc and F(ab')2 fragments using resin-bound IdeS (FragIT kit, #A0-FR6; Genovis). The Fc fragment was removed using a protein A column. A final concentration of 75 μg / ml of polyclonal F(ab')2 was used. Biotinylated donkey anti-sheep IgG (H+L) (#713-065-003, Jackson ImmunoResearch) was used to detect sheep anti-human C1q F(ab')2. SA-PE was diluted in D-MEM (+0.5% BSA) and used as a detection fluorescent dye.

[0257] C4d complement binding was assessed by incubation with biotinylated mouse anti-human C4d antibody (#A213; Quidel). SA-PE was diluted in D-MEM (+0.5% BSA) and used as a detection fluorescent dye. Finally, cells were transferred to FACS tubes and analyzed for mean fluorescence intensity (MFI) of cells in FL2 using an Accuri C6 cell fluorometer.

[0258] result

[0259] Complement deposition based on target cell-bound IgG can initiate the classical complement pathway, which can lead to the formation of the membrane attack complex (MAC), resulting in cell death. The early stages of the complement cascade promoted by antibody binding can also mark cells for complement-mediated phagocytosis through complement receptors. Therefore, pre-existing and induced antibodies against CAR T cells can limit the persistence of CAR-T in patients.

[0260] Complement deposition by IgG-coated cells was investigated using CD20-positive Daudi cells opsonized with RTX and then incubated with the indicated concentrations of IdeS or EndoS. Human serum was added as a complement source two hours later and for another two hours. Cells were aliquoted and stained using anti-human C1q or C4d specific detection antibodies and SA-PE as a fluorescent dye. The MFI of cells was analyzed by single-cell flow cytometry.

[0261] IdeS and EndoS prevented the deposition of C1q and C4d of IgG (see Figure 1). This suggests that IgG-sensitized CAR T cells will also be protected from complement deposition by treatment with IdeS or EndoS, and this is also expected to apply to light chain-specific CAR-T cells.

[0262] Example 2: Complement Dependent Cytotoxicity (CDC)

[0263] Binding of antibodies to receptor molecules (including pre-existing or induced CAR-specific antibodies) can lead to full complement activation, resulting in the formation of cytotoxic MACs. To mimic this, Daudi cells were incubated with the CD20 receptor-specific antibody RTX and investigated whether CDC could be prevented by treatment with IdeS or EndoS.

[0264] Daudi cells (3x10E6) were incubated with IdeS or EndoS (50 μg / ml) and titrated concentrations of rituximab (RTX) (50 μg / ml in each well, serially diluted 1:2 to 0.2 μg / ml) in a master plate at 37°C for 60 min.

[0265] 50 μl of the cell mixture was transferred to an ELISA plate with 50 ul of baby rabbit serum (1:5 dilution) as a complement source and incubated at 37°C for 45 minutes for CDC lysis. 10 ul of CCK8 was added to each 100 ul mixture and incubated in a CO2 incubator for another 60 minutes at 37°C. HCl (50 ul, 0.1 M) was used as a stop solution. OD values ​​were obtained at 450 nm. The OD values ​​of the wells without RTX were set to 100% survival.

[0266] result

[0267] At an RTX concentration of 0.78 μg / ml, 70% of the cells in the medium group died, whereas in the presence of IdeS or EndoS, all Daudi cells survived at this concentration (see Figure 2). The protective effect of EndoS decreased with increasing RTX concentration, falling to 30% survival at 50 μg / ml, although this concentration was 60 times higher than the RTX concentration of 0.78 μg / ml, and survival was the same as at 0.78 μg / ml in the absence of EndoS. Thus, even at high antibody concentrations (50 μg / ml), IdeS can protect against CDC, while EndoS also exhibits strong protective activity. This is expected to also apply to light chain-specific CAR-T cells.

[0268] Example 3 - ADPC of THP1 effector cells against RTX-conditioned Daudi cells

[0269] These experiments addressed the question of whether IdeS and EndoS reduce FcγR-mediated phagocytosis (ADCP), a mechanism that may limit CAR T cell persistence in the presence of preexisting or induced CAR-specific antibodies.

[0270] Cell culture

[0271] THP1 (monocyte effector cells) and Daudi target cells were expanded in complete glutamine D-MEM (5% FCS and PEST), washed, and diluted in D-MEM10 medium before experiments.

[0272] Target cell labeling

[0273] Prior to labeling, Daudi cells were washed twice in PBS to remove proteins. Cells were resuspended in PBS and stained with calcein (4 μL of 1 mg / mL calcein added to 6 mL of cells) and incubated at RT in the dark. After 15 min, cells were washed twice in culture medium (0.5% BSA) and incubated at 2x10 6 Resuspend cells / mL in 3 mL D-MEM 10 medium.

[0274] Effector cell markers

[0275] THP1 cells were washed twice in PBS to remove proteins and resuspended in 5 mL PBS. FarRed was added (5 μL FarRed was added to 5 mL cells) and incubated at RT in the dark. After 20 min, cells were washed twice in culture medium and cultured at 3.6 × 10 6 Resuspend in D-MEM 10 at 10 cells / mL.

[0276] Target effector cell incubation

[0277] Titrated RTX and enzyme (IdeS or EndoS) were incubated at 37°C for 60 minutes. Daudi target cells (50 μl, 2x10E6 / ml) were incubated for 30 minutes for opsonization, and then THP1 effector cells (50 μl, 3.6x10E6 / ml) were added and incubated for approximately 2 hours to allow ADCP of Daudi cells. Cells were fixed with 5% PFA for 3 minutes, washed and transferred for FACS analysis. The MFI of cells in FL2 (calcein) and FL4 (FarRed) was analyzed using an Accuri C6 flow cytometer. Double positive cells were considered to be ADCP positive.

[0278] result

[0279] The effectiveness of IdeS and EndoS in protecting RTX-opsonized CD20-positive Daudi cells from FcγR-mediated phagocytosis by monocytic THP1 effector cells was analyzed by flow cytometry. Briefly, Daudi cells opsonized with RTX were treated with increasing concentrations of calcein-labeled Daudi cells before adding a fixed concentration of IdeS or EndoS. After incubation for 30 minutes at 37°C, FarRed-labeled THP1 effector cells were added for approximately two hours. The washed and fixed cells were then analyzed by flow cytometry. All cells positive for calcein in FL2 were gated and defined as 100% Daudi cells. All FL2-positive cells were then gated in FL4 for RarRed positivity. These calcein / FarRed double-positive cells are Daudi cells phagocytosed by THP1. Removal of the Fc portion by IdeS completely abolished the ability of THP1 cells to phagocytose opsonized Daudi cells. Deglycosylation of the N297 position of RTX by EndoS also resulted in a reduction in phagocytosis in this model (see Figure 3 ).

[0280] Thus, in terms of ADCP, engulfment of antibody-opsonized cells of the monocytic cell line THP1 was completely prevented by IdeS treatment and reduced by EndoS treatment. This is expected to also apply to light chain-specific CAR-T cells.

[0281] Example 4 - Platelet Protection in the Immune Thrombocytopenia (ITP) Model

[0282] As demonstrated above using RTX and Daudi cells, IdeS and EndoS mitigate the effector function of cell surface receptor-specific antibodies. The following experiments used an in vitro thrombocytopenia (ITP) model to investigate in vivo whether these enzymes can also protect antibody-sensitized endogenous cells from elimination. This suggests that harmful polyclonal antibodies against cell surface receptors can be inactivated by treatment with imlifidase or EndoS, thereby mimicking the effects of these enzymes on CAR T cell persistence in the context of anti-CAR antibodies.

[0283] EndoS processing in vivo in ITP

[0284] Nine-week-old female Balb / c JBomTac Mice were induced with immune thrombocytopenia (ITP) by a single 200 μl ip injection of anti-platelet specific antibodies (anti-PLT IgG) (50 μg IgG / each mouse) purified from rabbit anti-mouse platelet serum (Cederland #CLA31440) by protein G. 30 minutes later, the specified amount of EndoS (10, 30, 90 μg / each mouse) was injected ip, with PBS as a negative control. Mice injected with vehicle solution (PBS) in both cases were used as normal controls. Mice were evaluated for hematoma or abnormal behavior 4 hours after injection. After 24 hours, blood samples were collected from the tail vein into Microvette CB300 (Sarstedt, Potassium-EDTA #16.444.100). Platelets in blood samples were counted using a hematology analyzer VetScan HM5.

[0285] Induction of ITP with anti-PLT antibodies cleaved by IdeS in vitro

[0286] Anti-mouse PLT IgG was purified from the serum of rabbits immunized with mouse platelets (Cat#CLA31440, Cederlane) by protein G. IgG was processed to generate IdeS cleavage product scIgG and fully cleaved Fc / F(ab')2 fragments for in vivo experiments.

[0287] Nine-week-old female Balb / c JBomTac Mice were injected with 250 μg / each mouse of anti-PLT IgG, scIgG or Fc / F(ab')2 fragments in a single 200 μl ip injection to induce ITP. Some mice were injected with PBS to establish normal platelet control levels. After 24 hours, blood samples were collected from the tail vein into Microvette CB300 (Sarstedt, Potassium-EDTA#16.444.100). Platelets in blood samples were counted using a hematology analyzer, VetScan HM5.

[0288] IdeS processing in vivo in ITPs

[0289] Nine-week-old female Balb / c JBomTacMice were injected with a single 200 μl ip injection of anti-PLT IgG (250 μg IgG / each mouse) purified from rabbit anti-mouse platelet serum (Cederland #CLA31440) by protein G to induce ITP. One hour after the ip injection of anti-PLT IgG, IdeS (0, 0.2, 2, 20 μg / each mouse) was administered iv. Control mice with normal platelet levels were injected with PBS only. After 24 hours, blood samples were collected from the tail vein into Microvette CB300 (Sarstedt, Potassium-EDTA #16.444.100). Platelets in blood samples were counted using a hematology analyzer, VetScan HM5.

[0290] result

[0291] The aim of this study was to evaluate the in vivo efficacy of IdeS cleavage products, scIgG or F(ab')2IgG fragments, as effector function modulators compared with intact anti-PLT IgG in vivo.

[0292] Immune thrombocytopenia (ITP) was induced in BALB / c mice by a single ip injection of rabbit anti-mouse platelet purified whole IgG, rabbit scIgG or F(ab')2 fragment at a dose of 0.25 mg / mouse. Mice were bled one day after induction of ITP and blood was collected through the tail vein. Platelets were automatically counted in VetScan HM5. Two naive mice that received only PBS were used as control mice. Their normal platelet level was 657x10 9 In contrast, the platelet count of mice injected with rabbit anti-mouse platelet purified IgG decreased to 86x10 9 Platelets / L (see Figure 4 ). However, a small decrease in platelets was seen in mice injected with anti-PLT scIgG. Induction of thrombocytopenia was not observed in mice treated with purified rabbit anti-mouse platelet F(ab')2 IgG fragment.

[0293] From this experiment, we can conclude that protection against thrombocytopenia can be achieved by in vitro generation of scIgG or F(ab′)2 by IdeS. Similar protective effects can be expected from other pre-existing or de novo antibodies targeting new epitopes on chimeric antigen receptor T cells, including light chain-specific CAR-T cells.

[0294] When scIgG preparations were injected, thrombocytopenia was partially prevented and completely abolished after IgG was cleaved into Fc and F(ab')2 fragments by IdeS (see Figure 4).

[0295] To investigate whether IdeS also has a therapeutic effect in vivo, mice were first injected with a dose of anti-PLT rabbit IgG that induces thrombocytopenia. One hour later, different doses of IdeS were injected. Blood was collected 24 hours later to establish platelet counts for different groups. 2 μg of IdeS per mouse was sufficient to rescue normal platelet levels in mice (see Figure 5 ). Therefore, the therapeutic effect of IdeS against harmful antiplatelet antibodies (anti-PLT) has been tested in vivo using an ITP mouse model. Injection of intact polyclonal anti-PLT rabbit antibodies (250 μg) into mice resulted in a strong ITP phenotype accompanied by platelet depletion.

[0296] Similar results were seen when EndoS was injected into anti-PTL IgG-sensitized mice. 50 μg of anti-PLT antibody was sufficient to reduce the platelet count from approximately 600 x 10E9 / L to 200 x 10E9 / L within 24 hours. 10 μg of EndoS per mouse was sufficient to protect mice from thrombocytopenia (see Figure 6 ).

[0297] These experiments suggest that the use of IdeS or EndoS can prevent or ameliorate the antibody-mediated effector functions of opsonized cells. Based on these data, it is expected that these enzymes will also improve the survival and efficacy of CAR T / -NK cells by enforcing pre-existing and treatment-induced ADA.

[0298] In conclusion, it has been shown that effector functions (C1q and C4d deposition, CDC, ADCP) mediated by the tested antibodies, which mimic ADA responses on CAR-T cells, can be prevented by using IdeS and EndoS.

[0299] Example 5

[0300] Experiments were performed to confirm whether antibodies directed against single-chain variable fragment (scFv) chimeric antigen receptors or against allogeneic epitopes on CAR-T cells have deleterious effects. Therefore, CAR-specific antibodies and allogeneic specific antibodies from different sources were tested for binding as well as Fc-mediated antibody effector functions, namely antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent cell-mediated cytotoxicity (ADCC) of CAR-T cells. In addition, it was demonstrated that imlifidase treatment can protect CAR-T cells from those deleterious IgG effector mechanisms.

[0301] Materials and Methods

[0302] cell

[0303] CAR-T cell lines, anti-CD19scFv (FMC63)-h(28ζ)CAR-Jurkat T-cells (CARJ-ZP005, Creative biolabs, Shirley, NY, USA) based on clone E6-1; Jurkat wild type (wt) (clone E6-1) (#EP-CL-0129, ElabScience, Houston, TX, USA); primary human CAR T cells, anti-BCMA4 CAR T-cells (BCMA-4-TM8-4-1BB-CD3ζCAR-T cells) (PM-CAR1037, ProMab Biotechnologies, Richmond, CA, USA); anti-CD19 CAR T-cells (CD19-scFv-Flag-TM--CD28-CD3ζCAR-T cells) (PM-CAR1007, ProMab Biotechnologies); blank scFv control T cells (PM-CAR1000, ProMab Biotechnologies). Anti-CD19-scFv is derived from the mouse CD19-specific monoclonal antibody FMC63.

[0304] THP-1 monocytic cell line (ACC16, DSMZ, Braunschweig, Germany). IgM BCR and CD20 positive Daudi cells (ACC78, DSMZ). All cells were cultured in complete RPMI 10 medium (RPMI, 10% FCS and PEST). Anti-CD19 CAR-Jurkat T cells were cultured under puromycin (1 mg / ml) selection.

[0305] Antibodies and human serum

[0306] CAR scFv cross-reactive anti-F(ab')2 specific antibodies include: affinity purified rabbit anti-human IgG, F(ab')2 fragment specific (#309-005-006, Jackson ImmunoResearch, West Grove, PA, USA); affinity purified rabbit anti-mouse IgG, F(ab')2 fragment specific (#315-005-006, Jackson ImmunoResearch); goat anti-human-IgG-Fc-PE (LS-AB2, OneLambda); and biotinylated goat anti-rabbit Fc (#111-066-046, Jackson ImmunoResearch). Biotinylated goat anti-rabbit Fc was detected using streptavidin-Alexa Fluor 647 (SA-AF647) (#016-600-084, Jackson ImmunoResearch).

[0307] Human male and female serum samples (n = 119) were purchased from BioIVT (BioIVT, Westbury, NY, USA) and used for quantification of human anti-mouse antibodies (HAMA) and allospecific antibody screening. Anonymous clinical research samples from highly HLA-sensitized patients (n = 8) and healthy volunteers in phase 1 (n = 11) were screened for HAMA and HLA alloreactivity of anti-CD19 CAR-Jurkat T cells. Control sera for HLA alloreactivity were purchased from OneLambda, including FlowPRA HLA class I positive control serum (FL1-PC, OneLambda, WestHills, CA, USA), FlowPRA HLA class II positive control serum (FL1-PC, OneLambda) and HLA negative control serum (LS-NC, LABScreen, OneLambda) or research samples donated by healthy donors.

[0308] ELISA-based HAMA detection

[0309] The bridge ELISA kit "LEGEND MAX Human Anti-Mouse Ig (HAMA)" (Catalog No. 438307, Lot No. B329842, BioLegend, San Diego, CA, USA) was used to detect HAMA in human serum. Briefly, the plate pre-coated with mouse IgG was washed and incubated with undiluted human serum samples (BioIVT), HAMA quality control, standard curve samples and mouse IgG conjugates. The contents were discarded and the plate was washed with wash buffer. The substrate solution was added and the plate was incubated in the dark at room temperature (RT) for 15 minutes. The stop solution was added to terminate the reaction. The absorbance at 450 nm and 570 nm was measured within 30 minutes using a SpectraMax i3x spectrophotometer (SpectraMaxi3x, Molecular Devices, San Jose, CA, USA). The OD results were analyzed using a 4-parameter logistic curve fitting algorithm in Graph Pad Prism 9 (GraphPad Software, San Diego, CA, USA). Serum samples with HAMA levels above 10 ng / ml were considered HAMA positive.

[0310] Flow cytometric screening of CAR-specific human sera

[0311] Anti-CD19 CAR-Jurkat or Jurkat wild-type T cells (1x10E5 / well) were washed in PBS and centrifuged at 300g for 5 minutes. The cell pellet was resuspended in 50 μl of human serum samples selected from ELISA-based HAMA detection. The serum-incubated cells were then washed and stained with goat anti-human Fc-PE antibody (OneLambda), and then the mean fluorescence intensity (MFI) level was analyzed in FL2 by flow cytometry (CytoFLEX flow cytometer, #C02945, Beckman Coulter).

[0312] Flow cytometric screening of CAR-T Jurkat alloreactive human sera

[0313] Anti-CD19 CAR-Jurkat T cells (1x10E5) were washed in PBS and centrifuged at 300g for 5 minutes. The cell pellet was resuspended in 50μl of the specified human serum sample. FlowPRA class I positive control serum (OneLambda), FlowPRA class II positive control serum (OneLambda), and HLA negative control serum (OneLambda) were used as controls. PE-conjugated goat anti-human IgG (LS-AB2, OneLambda) was used to detect bound allogeneic antibodies. After the washing step, the cells were resuspended in PBS and the MFI values ​​were analyzed using a flow cytometer (CytoFLEX).

[0314] Polyclonal IgG binding to primary CAR-T

[0315] Primary human CAR T cells (including anti-BCMA4 CAR T cells (PM-CAR1037, ProMab Biotechnologies), anti-CD19 CAR T cells (PM-CAR1007, ProMab Biotechnologies)) and blank scFv control cells (PM-CAR1000, ProMab Biotechnologies) were thawed, washed, and incubated with rabbit anti-mouse IgG (F(ab')2 specific) (#315-005-006, Jackson Immuno Research) for 30 minutes. Daudi cells expressing BCR were stained as F(ab')2 positive controls. The cells were then washed and incubated successively with biotinylated goat anti-rabbit Fc antibodies and SA-AF647 (#016-600-084, Jackson Immuno Research). A similar method was used to evaluate the binding of polyclonal anti-mouse and anti-human IgG antibodies to anti-CD19 CAR-Jurkat T cells.

[0316] Antibody-dependent cellular phagocytosis (ADCP) using effector cells expressing FcγRI

[0317] Anti-CD19 CAR-Jurkat T cells were incubated with serum and tested for ADCP induction using the FcγRI reporter bioassay kit (#CS1781C01, Promega, Madison, WI, USA). Briefly, human serum samples (BioIVT and anonymous serum from the 06 study), HLA class I positive control serum (FL1-PC, OneLambda), and HLA negative control serum (#LS-NC, OneLambda) were incubated at 37°C for 30 minutes with or without 10 μg / mL imlifidase. Anti-CD19 CAR-Jurkat target T cells (CARJ-ZP005, Creative Biolabs) (7500 / well) were centrifuged, washed once in D-PBS, and resuspended in the provided assay buffer (4% low IgG serum in RPMI-1640). Target cells were incubated with Imlifidase-treated / untreated antibodies and serum at 37°C for 1 hour. Subsequently, effector cells expressing FcγRI (75,000 / well) (Promega) were added to the opsonized target cells and incubated at 37°C for 6 h. Finally, the cells were incubated with Bio-Glo TM Luciferase assay reagent (Promega) was incubated at ambient temperature for 10 minutes, and then luminescence reader (SpectraMax i3x) was used to measure luciferase activity, wherein the integration time was set to 0.5 seconds / well. GraphPadPrism 9.0 (GraphPad Software, SanDiego, CA, the United States) was used to analyze the data. Plate background was calculated as the average of three replicates including assay buffer, and no antibody control was calculated as the average of replicates containing only cells in the presence / absence of imlifidase. Induction fold (FoI) was calculated as follows, FoI=RLU (induction-background) / RLU (no antibody control-background).

[0318] Antibody-dependent cell-mediated cytotoxicity (ADCC) using effector cells expressing high-affinity FcgRIIIa (V158) and low-affinity FcgRIIIa (F158)

[0319] Antibodies (rituximab, MabThera, Roche, Basel, Switzerland), rabbit anti-human IgG (F(ab')2 specific) (Jackson Immuno Research), rabbit anti-mouse IgG (F(ab')2 specific) (Jackson Immuno Research), and human serum (BioIVT and anonymous serum from highly HLA-sensitized patients) were incubated at 37°C for 30 min in the presence or absence of 20 μg / mL imlifidase and then stored at 4°C overnight. Target cells (7500 cells / well), including anti-CD19 CAR-Jurkat (CARJ-ZP005, Creative Biolabs), Jurkat wt cells (EP-CL-0129, Elabscience, Houston, TX, USA), and Daudi cells (ACC78, DSMZ, Braunschweig, Germany) were centrifuged, washed once in D-PBS (GIBCO Life Technologies, GrandIsland, NY, USA), resuspended in assay buffer (4% low IgG serum in RPMI-1640 (Promega, Madison, WI, USA), and incubated with imlifidase-treated / untreated antibodies and serum for 1 h at 37°C. Afterwards, 75,000 effector cells expressing low-affinity (#G979A, Promega) or high-affinity (#G701A, Promega) FcγRIIIa were added to the opsonized target cells and incubated at 37°C for 6 hours. Finally, the cells were incubated with Bio-Glo TM Luciferase assay reagent (Promega) was incubated at ambient temperature for 10 minutes, and then luminescence reader (SpectraMax i3x) was used to measure luciferase activity, wherein the integration time was set to 0.5 seconds / well. Raw data were exported and analyzed using GraphPad Prism 9.0 (GraphPad Software). Plate background was calculated as the mean value of three replicates including assay buffer, and no antibody control was calculated as the mean value of the replicates of cells only including the presence / absence of imlifidase. HLA negative controls were also included, representing serum samples from healthy donors, which did not contain quantifiable anti-HLA class I and class II antibodies. Induction multiple (FoI) was calculated as follows, FoI=RLU (induction-background) / RLU (no antibody control-background).

[0320] Flow cytometry-based ADCP assay

[0321] ADCP target cells (anti-CD19 CAR-Jurkat T cells, Jurkat wt T cells, and Daudi cells) were first stained with calcein-AM (C3099, Invitrogen, Carlsbad, CA, USA) and then incubated with imlifidase-treated (+ / -10 μg / mL) rabbit anti-human IgG (F(ab')2 specific) antibody (#309-005-006, Jackson ImmunoResearch) or anti-mouse IgG (F(ab')2 specific) antibody (#315-005-006, Jackson ImmunoResearch) at the indicated concentrations. Alternatively, target cell pellets were resuspended in human serum samples (25 μl) treated with imlifidase (+ / -10 μg / mL) for opsonization with HAMA or allogeneic IgG. The monocytic effector cell line THP-1 was stained with CellTrace FarRed DDAO-SE (C34553, Molecular Probes, Eugene, OR, USA) and then added to the target cells and incubated for 90 minutes at 37°C. Phagocytosis was assessed by flow cytometry (CytoFLEX flow cytometer, #C02945, Beckman Coulter). The number of FL1 and FL4 double-positive cells, reflecting the target cells engulfed by THP1 cells, was expressed as a percentage of target cells.

[0322] CD19-protein binding blocking assay

[0323] Rabbit anti-mouse IgG (F(ab')2 specific antibody) (Jackson ImmunoResearch Laboratories) was incubated with human serum (BioIVT) at 37°C for 60 minutes with or without 10 μg / ml imlifidase. In the next incubation step, IHAc (1mM) (I4386, Sigma-Aldrich, St.Louis, MO, USA) was added to all samples for 30 minutes to inactivate imlifidase. Anti-CD19CAR-Jurkat and Jurkat wt T cells were incubated with the prepared serum and IgG samples at RT for 60 minutes. Recombinant human CD19-Fc chimeric protein (atto 647N conjugated) (ATM9269, R&D systems, Minneapolis, MN, USA) was added to the cells and incubated for 45 minutes, and then analyzed by flow cytometry (CytoFLEX flow cytometer, #C02945, Beckman Coulter).

[0324] result

[0325] F(ab')2-specific polyclonal antibody specifically binds to CAR T cell receptor

[0326] Primary human T cells were transfected with anti-CD19 or BCMA-specific chimeric antigen receptors to generate autologous CAR T cells for identification of CAR-specific antibodies. When the antigen-specific scFv domains of CARs are derived from, for example, mouse monoclonal antibodies, they contain epitopes that are foreign to their receptors, even in the case of autologous CAR T cell therapy. In order to study the effects of CAR-specific antibodies on CAR T cells, the binding of CAR-specific antibodies from different sources was tested. Polyclonal rabbit anti-mouse F(ab')2-specific antibodies showed binding to anti-CD19 CAR T cells ( Figure 7 A) and anti-BCMA-CAR T cells ( Figure 7 B) cross-reactivity, while blank transfected T cells ( Figure 7 C) remains unstained. Daudi cells expressing the B cell receptor (BCR) have previously been shown to be cross-reactive with the polyclonal rabbit anti-mouse F(ab')2 detection reagent. Figure 7 D) Staining for F(ab')2 positive control. Staining of the human T cell line Jurkat transduced with anti-human CD19 CAR (in which the scFv of the receptor is based on the mouse mAb FMC63) demonstrated strong binding of the rabbit anti-mouse F(ab')2 antibody. Some cross-reactions were even observed using rabbit anti-human F(ab')2. These data confirm that a variety of different receptor constructs for different targets can bind to the antibody. This binding may have a negative impact on adoptive cell transfer immunotherapies such as CART cell therapy, so these antibodies were further used to study the effector functions mediated by anti-CAR T cell antibodies and the extent to which these effector functions can be prevented by treatment with imlifidase.

[0327] Identification of HAMA and CD19-CAR Jurkat T cell allogeneic-specific sera

[0328] One group of antibodies that may be specific for CARs is human anti-mouse antibodies (HAMA). HAMA levels in human serum samples can be quantified in a sandwich ELISA using assay plates coated with mouse IgG. A validated HAMA ELISA kit is used to screen for HAMA in human serum ( Fig. 8A ). Selected identified HAMA-positive and HAMA-negative samples were tested for binding to anti-CD19 CAR-Jurkat T cells. Jurkat wt T cells were included to distinguish binding of HAMA-specific IgG from HLA alloreactivity. It could be demonstrated that ELISA HAMA-positive sera also specifically bound to the anti-CD19 CAR T cell receptor ( Figure 8B). Sera screened by ELISA for HAMA are depicted ( Figure 8C ). These samples were then further screened for IgG binding by flow cytometry. This allowed the selection of HAMA or anti-CD19 CAR T cell alloreactive sera to further dissect the impact of these different IgG groups on anti-CD19 CAR-Jurkat T cells. HAMA is believed to be induced in normal individuals by exposure to murine antigens. It is expected that the frequency and concentration of HAMA will be higher in patients receiving murine mAb-based biologics, in some cases even leading to partial neutralization of these therapeutics. Higher levels of allogeneic antibodies against anti-CD19 CAR-Jurkat T cells can be detected in the sera of HLA-sensitized transplant patients compared to healthy individuals ( Fig.8D Five of the eight screened highly anti-HLA sensitized patients were positive, and one patient was highly anti-HLA sensitized for anti-CD19 CAR-Jurkat T cells. Two screened individuals had no allogeneic antibodies to anti-CD19 CAR Jurkat cells.

[0329] These data demonstrate that antibodies capable of binding to the receptor construct are detectable in human patients, including healthy individuals, and are increased in patients who have undergone treatments that increase HLA sensitization, such as transplantation.

[0330] Allogeneic antibodies can be induced not only in organ transplantation but also due to pregnancy and blood transfusion. Infusing allogeneic cell therapy into patients may be an additional inducer of allogeneic antibodies, which may pose a problem for allogeneic CAR T-cell therapy.

[0331] Imlifidase treatment prevents the ADCP opsonization of polyclonal anti-F(ab')2 antibodies against CD19CAR-T cells. And imlifidase prevents allogeneic serum-opsonized CD19-CAR Jurkat T cells from inducing ADCP

[0332] The induction of antibody-mediated cellular phagocytosis (ADCP) and its prevention by treatment with the IgG-cleaving enzyme imlifidase were tested for polyclonal anti-F(ab')2 antibodies (specific for the CD19 scFv CAR domain) and HLA-specific antibodies (directed to allogeneic anti-CD19 CAR-Jurkat T cells) (see Fig. 9 and Fig.10 The flow cytometry-based ADCP model was used with calcein-stained target cells and CellTrace FarRed-labeled mononuclear THP1 effector cells. Cell collection by flow cytometry enabled the distinction of single-positive cells from double-positive cells, i.e., phagocytosed cells. Rabbit anti-mouse F(ab')2 ( Fig. 9 A) or cross-reactive anti-human F(ab')2 antibody ( Fig. 9B) Opsonization of anti-CD19 CAR-Jurkat target cells. In both cases, addition of imlifidase (10 μg / mL) prevented ADCP of target cells. There was no uptake of Jurkat wt cells, indicating that phagocytosis was anti-CD19 CAR-dependent ( Fig. 9 D, E). BCR-positive Daudi target cells were used as a positive control for F(ab')2 antibody-mediated ADCP ( Fig. 9 C, F). These data suggest that receptor-specific antibodies can induce ADCP against T cells, which is expected to negatively impact cell therapy. The data also suggest that treatment with imlifidase effectively prevents ADCP. In addition, human sera sensitized to allogeneic Jurkat CAR T cells were tested for opsonization and induction of ADCP using a bioluminescent FcγRI reporter assay (#CS1781C01, Promega, #CS1781C01). Fig.10 A) and highly anti-HLA sensitized patients ( Fig.10 B) serum was able to opsonize anti-CD19 CAR-Jurkat T cells and induce ADCP. ADCP induction of allogeneic cells by serum IgG can be reduced by treatment with imlifidase. Therefore, these data confirm that antibodies in sera from normal individuals and sensitized patients induce ADCP against adoptive cell transfer immunotherapy cells, but this can be reduced by imlifidase treatment.

[0333] Imlifidase treatment prevents the FcγRIIIa allele (V158) and allele (F158) from expressing anti-CD19CAR ADCC induced by heterologous antibody (V158).

[0334] Antibody-dependent cellular cytotoxicity (ADCC) is triggered by the engagement of FcγRIIIa (CD16a) on effector cells with IgG-opsonized target cells. Two major CD16a alleles exist in the general population, a high-affinity variant with valine at position 158 (V158) and a low-affinity variant with phenylalanine at position 158 (F158). These alleles were introduced into effector cells for the ADCC bioluminescent assay (Promega). Anti-CD19 CAR-Jurkat T cells were incubated with rabbit anti-mouse ( Fig.11 A) or anti-human ( Fig.11 B) Incubation with F(ab')2 antibody. The opsonized target cells were incubated with high affinity FcγRIIIa(V158) effector cells. ADCC was strongly induced in the target cells opsonized with anti-mouse F(ab')2 antibody. ADCC induction was completely abolished in the samples treated with imlifidase ( Fig.11A). Polyclonal anti-human F(ab')2 induced weaker stimulation but could trigger ADCC at 100 μg / mL ( Fig.11 B), this effect was not found in negative control Jurkat wt cells ( Fig.11 C). Rituximab ( Fig.11 D) or anti-human F(ab')2( Fig.11 E) Opsonized Daudi cells were used as a positive control. In addition, imlifidase treatment of opsonized Daudi target cells prevented the induction of ADCC ( Fig.11 D, E).

[0335] Similar results were seen using a low affinity FcγRIIIa ADCC bioluminescent reporter assay ( Fig.12 ). Anti-mouse F(ab')2-treated anti-CD19 CAR-Jurkat T cells induced ADCC signaling, which could be prevented by treatment with imlifidase ( Fig.12 A). On the other hand, polyclonal anti-human F(ab')2 antibodies were unable to trigger ADCC signaling even at the highest (100 μg / mL) antibody concentration ( Fig.12 B). With rituximab ( Fig.12 D) or anti-human F(ab')2( Fig.12 E) Co-incubated Daudi cells induced low-affinity FcγRIIIa ADCC, whereas imlifidase treatment prevented this effect.

[0336] These data further suggest that receptor-specific antibodies can mediate deleterious effects on cells in adoptive cell transfer immunotherapy, particularly ADCC, which is expected to have a negative impact on cell therapy. The data also show that treatment with imlifidase is effective in preventing ADCC.

[0337] Induction of ADCC by HAMA-opsonized anti-CD19 CAR-Jurkat T cells is prevented by imlifidase treatment

[0338] ELISA-HAMA negative (164) and positive sera (184, 187, 208, 250) treated with or without 20 μg / mL imlifidase were incubated with anti-CD19 CAR-Jurkat T cells, and then the opsonized target cells were added to effector cells transfected with the FcγRIIIa high affinity allele (Promega). The bioluminescent signal from the two HAMA positive sera (184, 250) was reduced in the presence of imlifidase ( Fig.13). This suggests that a portion of mouse IgG in human serum binds to HAMA antibodies and binds to anti-CD19 CAR, thereby triggering the CD16 FcγRIIIa of effector cells. Therefore, these data further suggest that antibodies in human serum mediate deleterious effects on cells in adoptive cell transfer immunotherapy, but this can be reduced by imlifidase treatment.

[0339] The binding of CD19 protein to anti-CD19 CAR T cells exposed to serum can be improved by imlifidase treatment. combine

[0340] For successful CAR T-cell therapy, the specific interaction of their chimeric antigen receptors with their target proteins is an essential step. Binding of serum IgG to anti-CD19 CARs may interfere with their cognate binding to, for example, CD19 on target cells. Fig.14 ) were tested for interference with the binding of recombinant atto-647N-tagged human CD19 protein to anti-CD19 CAR-Jurkat T cells. In most samples, digestion of serum IgG by imlifidase resulted in an increase in the median FI signal from anti-CD19 CAR-Jurkat T cells, indicating increased binding of atto-647N-tagged CD19 protein. This suggests that the interaction of adoptive cellular immunotherapy (e.g., anti-CD19 CAR T cells) with its target protein can be increased by treatment with imlifidase to remove only the IgG-Fc portion, which can reduce steric hindrance. The in vitro effect of imlifidase may be stronger in vivo, as the half-life of the blocking F(ab')2 fragment will be shorter than its intact IgG equivalent.

[0341] Example 6 - Elimination of cytokines in CAR-T cells cultured with soluble immunoglobulins in the presence of IdeS The birth of the child

[0342] introduce

[0343] This study investigated whether CAR-T cell constructs directed against immunoglobulin light chains (e.g., constructs disclosed in Ranganathan et al., Clin Cancer Res, 2021 and Vera et al., Blood 2006; 108) exhibit baseline production of cytokines IFNg and IL-2 in the presence of immunoglobulins. It was also investigated whether adding IdeS to the suspension would result in cleavage of soluble immunoglobulins and reduce or eliminate cytokine production.

[0344] method

[0345] In the first experiment, T cells were isolated from peripheral blood mononuclear cells obtained from two healthy human donors. T cells were transduced with either a CD19-targeted CAR construct (CD19.CAR) or a kappa light chain-targeted CAR construct (κ.28). A population of non-transduced cells (NTD) served as a negative control. The cells were then placed in four different culture conditions with increasing concentrations of soluble immunoglobulin in each condition. IdeS was then added to each group of similarly seeded CAR-T cells to observe changes in cytokine production.

[0346] In the second experiment, the first experiment was repeated with a second light chain targeting construct, λ light chain targeting CAR (λ.28). T cells obtained from healthy human donors were used and transduced with CD19.CAR, κ.28, λ.28 or not (NTD). Cells were inoculated with the same soluble immunoglobulin concentration as before and IdeS was added again or not.

[0347] result

[0348] As shown in Figure 1, NTD cells and CD19.CAR did not produce any interferon gamma (IFNγ) regardless of the concentration of soluble immunoglobulin in the serum. This confirms that the assay is valid because NTD cells and CD19.CAR do not recognize soluble immunoglobulin.

[0349] κ.28 T cells produced IFNγ in the presence of soluble immunoglobulins, demonstrating baseline cytokine production. In addition, the higher the concentration of soluble immunoglobulins in the serum, the more IFNγ was produced. However, when IdeS was added to similarly vaccinated κ.28 cells, IFNγ production was abolished. These results were reproducible in both donors. These data suggest that light chain-specific CAR-T cells can be stimulated by soluble immunoglobulins outside the tumor and that this stimulation can be abolished by IdeS. Therefore, it is expected that IdeS administration will help maintain CAR-T cell activity and reduce exhaustion.

[0350] In the second experiment, similar results were observed, such as Figure 2 As shown. These data confirm that light chain-specific CAR-T cells can be stimulated by soluble immunoglobulins outside the tumor and that this stimulation can be eliminated by IdeS. Therefore, it is expected that IdeS administration will help maintain CAR-T cell activity and reduce exhaustion. The λ.28 construct produced the least IFNγ, which may be due to the fact that the soluble human immunoglobulin serum used was polyclonal and the κ:λ ratio was 2:1, which is the same as what occurs naturally in the human body. Therefore, the amount of λ light chain in the soluble immunoglobulin serum used may be insufficient to trigger cytokine production.

[0351]

[0352]

[0353]

[0354]

[0355]

[0356]

[0357]

[0358]

[0359]

[0360]

[0361]

[0362]

[0363]

[0364]

[0365]

[0366]

[0367]

[0368]

[0369]

[0370]

[0371]

[0372]

[0373]

[0374]

[0375]

[0376]

[0377]

[0378]

[0379]

[0380]

[0381]

[0382]

[0383]

[0384]

[0385]

[0386]

[0387]

[0388]

[0389]

[0390]

[0391]

[0392]

[0393]

[0394]

[0395]

[0396]

[0397]

[0398]

[0399]

[0400]

[0401]

Claims

1. A method for improving the benefit of adoptive cell transfer immunotherapy targeting immunoglobulin light chains to a patient, comprising administering a protein having IgG cysteine ​​protease or IgG endoglycosidase activity in combination with the adoptive cell transfer immunotherapy.

2. A method for treating cancer comprising administering a protein having IgG cysteine ​​protease or IgG endoglycosidase activity in combination with adoptive cell transfer immunotherapy targeting immunoglobulin light chains.

3. The method according to claim 1 or 2, wherein: The protein having IgG cysteine ​​protease or IgG endoglycosidase activity is administered prior to administration of the adoptive cell transfer immunotherapy, or wherein the protein having IgG cysteine ​​protease or IgG endoglycosidase activity is administered after administration of the adoptive cell transfer immunotherapy.

4. A method for treating cancer comprising administering a protein having IgG cysteine ​​protease or IgG endoglycosidase activity to a patient who has previously received and / or is scheduled to receive adoptive cell transfer immunotherapy targeting immunoglobulin light chains.

5. A method of treating cancer comprising administering adoptive cell transfer immunotherapy targeting immunoglobulin light chains to a patient who has previously received and / or is scheduled to receive a protein having IgG cysteine ​​protease or IgG endoglycosidase activity.

6. A method of treating an antibody-mediated autoimmune disease, wherein the treatment comprises administering adoptive cell transfer immunotherapy targeting immunoglobulin light chains to a patient who has previously received and / or is scheduled to receive a protein having IgG cysteine ​​protease or IgG endoglycosidase activity; Optionally, the antibody-mediated autoimmune disease is selected from the group consisting of: juvenile arthritis (particularly juvenile idiopathic arthritis), rheumatoid arthritis, generalized lichen myxedema (scleromyxedema), Graves' disease, IgA-driven bullous dermatosis, IgG4-driven bullous pemphigoid, Sjögren's syndrome and lupus mastitis.

7. A method according to any one of the preceding claims, wherein: The adoptive cell transfer immunotherapy targeting immunoglobulin light chains comprises administering T cells, natural killer cells or dendritic cells expressing chimeric antigen receptors or T cell receptors.

8. The method according to claim 7, wherein: The chimeric antigen receptor or T cell receptor comprises a binding domain, such as a scFv, that specifically binds an immunoglobulin light chain, such as a human kappa immunoglobulin light chain or a human lambda immunoglobulin light chain.

9. A method according to any one of the preceding claims, wherein: The methods increase the activity, survival and / or proliferation of cells administered in the adoptive cell transfer immunotherapy.

10. A method according to any one of the preceding claims, wherein: The method reduces antibody-mediated complement deposition, complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), exhaustion, receptor-activated cell death, receptor blockade and / or immunoglobulin cross-linking of cells administered in the adoptive cell transfer immunotherapy.

11. A method according to any one of the preceding claims, wherein: The disease is cancer, and the cancer is a B-cell tumor, such as a B-cell lymphoma or a B-cell leukemia.

12. A method according to any one of the preceding claims, wherein: (i) the protein having IgG cysteine ​​protease activity is an IgG cysteine ​​protease from a bacterium of the genus Streptococcus, such as Streptococcus pyogenes, optionally wherein the protein is IdeS or IdeZ; or (ii) the protein having IgG endoglycosidase activity is an IgG endoglycosidase from a Streptococcus bacterium, such as Streptococcus pyogenes, Streptococcus equi or Streptococcus zooepidemicus, or an IgG endoglycosidase from Corynebacterium pseudotuberculosis, Enterococcus faecalis or Elizabethella meningoseptica, optionally wherein the protein is EndoS, CP40, EndoE or EndoF2.

13. The method according to claim 12, wherein: (i) the protein having IgG cysteine ​​protease activity is a polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 2, 4, 5 or 91 or a fragment or variant thereof having IgG cysteine ​​protease activity; or (ii) The protein having IgG endoglycosidase activity is a polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO: 90 or a fragment or variant thereof having IgG endoglycosidase activity.

14. The method according to claim 13, wherein: (i) the protein having IgG cysteine ​​protease activity is a polypeptide having a sequence that is at least 80% identical, such as at least 85%, 90%, 95% or 99% identical to SEQ ID NO: 2, 4, 5 or 91, or wherein the IgG cysteine ​​protease comprises or consists of the sequence of any one of SEQ ID NO: 6-25 and 55-69, optionally wherein the sequence includes an additional methionine at the N-terminus and / or a histidine tag at the C-terminus; or (ii) The protein having IgG endoglycosidase activity is a polypeptide having a sequence that is at least 80% identical to SEQ ID NO:90, such as at least 85%, 90%, 95% or 99% identical.

15. A protein having IgG cysteine ​​protease or IgG endoglycosidase activity for use in regulating or preparing a patient for adoptive cell transfer immunotherapy targeting immunoglobulin light chains, for use in improving the benefit of adoptive cell transfer immunotherapy targeting immunoglobulin light chains to a patient, or for use in reducing plasma IgG levels or reducing the binding of complement or Fc receptors to plasma IgG molecules in a patient undergoing or planning to undergo adoptive cell transfer immunotherapy targeting immunoglobulin light chains.

Citation Information

Cited By

  • Combination of reagents for detecting ADCP activity of human immune globulin to non-human species cells, detection kit and detection method thereof

    CN120334552A

  • A combination of detection reagents for detecting ADCP activity of human immunoglobulin on non-human cells, a detection kit and a detection method thereof

    CN120334552B